Additives for reducing non-specific interactions between fluorescent polymer conjugates and cells in biological samples
Patent Information
- Application Number
- JP2023528434
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-13
- Filing Date
- 2021-11-12
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-11-12
AI Technical Summary
Polymer dye conjugates exhibit non-specific binding to cells in biological samples, leading to misinterpretation and false positive results in assays like flow cytometry.
The use of zwitterionic or anionic surfactants is applied before, during, or after contacting the dye conjugate with the biological sample to reduce non-specific binding, specifically with leukocytes in blood samples.
The method significantly reduces non-specific binding of polymer dye conjugates to monocytes and granulocytes, enhancing the accuracy of flow cytometry assays by minimizing false positive signals.
Smart Images

Figure 2022104147000001 
Figure 2022104147000002 
Figure 2022104147000003
Abstract
Description
[Technical Field]
[0001] This application was filed as a PCT international patent application on November 12, 2021, and claims the benefit of priority to U.S. Provisional Application No. 63 / 113,703, filed on November 13, 2020, which is incorporated herein by reference in its entirety. [Background technology]
[0002] background Polymer dye conjugates are bright and offer excellent performance that can be utilized in single-color or multicolor flow cytometry assays. Generally, polymer dye conjugates exhibit high brightness due to their unique and complex structure. However, the same unique and complex structure may also bring about some significant limitations. The present disclosure addresses these limitations. Summary of the Invention [Means for solving the problem]
[0003] summary By their nature, polymer dye conjugates can bind nonspecifically to cells in biological samples, such as monocytes and granulocytes in peripheral blood samples. Nonspecific binding can lead to misinterpretation and false positive results. For example, when a polymer dye conjugate comes into contact with blood during the analysis of cell markers, the conjugate can bind nonspecifically to cells, such as monocytes and / or granulocytes, thereby resulting in a signal that can be erroneously interpreted as a positive population or resulting in the extraction of populations other than the desired one.
[0004] The present disclosure provides solutions to these and other problems associated with the use of polymer-dye conjugates. In some embodiments, the present disclosure provides a composition for reducing or eliminating nonspecific binding of a dye conjugate to cells in a biological sample, the composition comprising a dye conjugate described herein and a surfactant.
[0005] In some embodiments, the present disclosure provides a method for reducing or eliminating nonspecific binding of at least one dye conjugate to cells in a biological sample, the method comprising contacting at least one dye conjugate with at least one zwitterionic surfactant before, during, or after contacting the dye conjugate with the biological sample, wherein the contacting results in a reduction in nonspecific binding of the at least one dye conjugate in the sample. In some embodiments, the present disclosure provides a method for reducing or eliminating nonspecific binding of at least one dye conjugate to cells in a blood sample, the method comprising contacting at least one dye conjugate with at least one anionic surfactant before, during, or after contacting the dye conjugate with the blood sample, wherein the contacting results in a reduction in nonspecific binding of the at least one dye conjugate in the blood sample. The compositions and methods of the present disclosure reduce or eliminate nonspecific binding of polymeric or non-polymeric dye conjugates to monocytes and / or granulocytes in a blood sample.
[0006] Provided is a method for reducing or eliminating nonspecific binding of at least one dye conjugate in a biological sample, such as a blood sample, comprising contacting the at least one dye conjugate with at least one zwitterionic or anionic surfactant before, during, or after contacting the polymer-dye conjugate with the biological sample, wherein the contacting results in a reduction in nonspecific binding of the at least one polymer-dye conjugate in the biological sample.
[0007] In some embodiments, the biological sample may be a blood sample. In some embodiments, the cells may be white blood cells, and the reduction in non-specific binding may include a reduction in non-specific binding to white blood cells in the blood sample. In some embodiments, the white blood cells are selected from the group consisting of monocytes and granulocytes.
[0008] In some embodiments, the method includes adding a surfactant to the polymer-dye conjugate before contacting the polymer-dye conjugate with the biological sample, such as a peripheral blood sample.
[0009] In some embodiments, the method includes adding a surfactant to the blood sample prior to contacting with the polymer-dye conjugate.
[0010] The surfactant has the formula: R 1’ [CO-X(CH2) j ] g -[N + (R 2’ )(R 3’ )] k -(CH2) f -[CH(OH)CH2] h -Y - (In the formula, R 1’ is saturated or unsaturated C 5~24 is alkyl; X is NH, NR 4 ', where R 4’ is C 1~4alkyl, O, or S; j is an integer from 1 to 10; g is 0 or 1; R 2’ and R 3’ independently C 1~4 is alkyl; k is 0 or 1; hydroxyl is optionally substituted with methyl, ethyl, hydroxymethyl, or hydroxyethyl; f is an integer from 0 to 4; h is 0 or 1; Y is COO, SO3, OPO(OR 5’ )O, or P(O)(OR 5’ )O, where R 5’ is H or C 1~4 alkyl) and when k=0, the surfactant may be in its acid form or its sodium or potassium salt.
[0011] In some embodiments, the surfactant has the formula: R 1’ [CO-X(CH2) j ] g -N + (R 2’ )(R 3’ )-(CH2) f -[CH(OH)CH2] h -Y - , (In the formula, R 1’ is saturated or unsaturated C 5~24 is alkyl; X is NH or NR 4’ where R 4’ is C 1~4 alkyl, O, or S; j is an integer from 1 to 10; g is 0 or 1; R 2’ and R 3’ independently C 1~4 is alkyl; hydroxyl is optionally substituted with methyl, ethyl, hydroxymethyl, or hydroxyethyl; f is an integer from 1 to 4; h is 0 or 1; Y is COO, SO3, OPO(OR 5’ )O or P(O)(OR 5’ )O, where R 5’ is H or C 1~4 alkyl residue) The surfactant may be a zwitterionic surfactant compound of the formula:
[0012] Zwitterionic surfactants have the formula: R 1’ -N + (CH3)2-CH2COO - ; R 1’ -CO-NH(CH2)3-N + (CH3)2-CH2COO - ; R 1’ -N + (CH3)2-CH2CH(OH)CH2SO3 - ;or R 1’ -CO-NH-(CH2)3-N + (CH3)2-CH2CH(OH)CH2SO3 - It may also be a compound of the formula:
[0013] In some embodiments, the zwitterionic surfactant is selected from the group consisting of almondamidopropyl betaine, apricotamidopropyl betaine, avocadoamidopropyl betaine, babassuamidopropyl betaine, behenamidopropyl betaine, behenyl betaine, canolamidopropyl betaine, capryl / capramidopropyl betaine, carnitine, cetyl betaine, cocamidoethy betaine, cocamidopropyl betaine, cocamidopropyl hydroxysultaine, coco betaine, coco hydroxysultaine, coco / oleamidopropyl betaine, coco sultaine, decyl betaine, dihydroxyethyl oleyl glycinate, dihydroxyethyl soy glycinate glycinate, dihydroxyethyl stearyl glycinate, dihydroxyethyl tallow glycinate, dimethicone propyl PG-betaine, drucamidopropyl hydroxysultaine, hydrogenated tallow betaine, isostearamidopropyl betaine, lauramidopropyl betaine, lauryl betaine, lauryl hydroxysultaine, lauryl sultaine, milk amidopropylamidopropyl betaine, milkamidopropyl betaine, myristamidopropyl betaine, myristyl betaine, oleamidopropyl betaine, oleamidopropyl hydroxysultaine, oleyl betaine, oliamidopropyl betaine, palmamidopropyl betaine, palmitamidopropyl betaine, palmitoyl carnitine, palm kernelamidopropyl betaine, polytetrafluoroethylene acetoxypropyl betaine, ricinoleamidopropyl betaine, sesamidopropyl betaine, soyamidopropyl betaine, stearamidopropyl betaine, stearyl betaine, tallowamidopropyl betaine, tallowamidopropyl hydroxysultaine, tallow betaine, tallow dihydroxyethyl betaine, undecylenamidopropyl betaine, and wheat germamidopropyl betaine. In some embodiments, the surfactant is lauryl betaine.
[0014] In some embodiments, the surfactant has the formula: R 1’ [CO-X(CH2) j ] g -(CH2) f -[CH(OH)CH2] h -Y - (In the formula, R 1’ is saturated or unsaturated C 5~24 is alkyl; X is NH, NR 4 ', where R 4’ is C 1~4 alkyl, O, or S; j is an integer from 1 to 10; g is 0 or 1; R 2’ and R 3’ independently C 1~4 is alkyl; hydroxyl is optionally substituted with methyl, ethyl, hydroxymethyl, or hydroxyethyl; f is an integer from 0 to 4; h is 0 or 1; Y is COO, SO3, OPO(OR 5’ )O or P(O)(OR 5’ )O, where R 5’ is H or C 1~4 In some embodiments, f=0. In some embodiments, f=1. In some embodiments, f=3. In some embodiments, f=4. In some embodiments, Y is COO or SO. In some embodiments, R 2’ and R 3’ is methyl.
[0015] Anionic surfactants are those having the formula R 1’ -CO-N(CH3)-CH2-COO - ;or R 1 '-CO-N(CH3)-CH2-SO3-(in the formula, R 1’ is saturated or unsaturated C 5~24 In some embodiments, R 1’ is saturated or unsaturated C 7~19 Alkyl, or C 11~17 It may also be alkyl.
[0016] In some embodiments, the anionic surfactant may be selected from the group consisting of N-lauroyl sarcosine, sodium lauroyl sarcosinate, sodium palmitoyl sarcosinate, sodium stearoyl sarcosinate, N-methyl-N-(1-oxotetradecyl)-glycine sodium salt, sodium caproyl sarcosinate, sodium capryloyl sarcosinate, N-methyl-N-(1-oxo-9-octadecen-1-yl)-glycine, sodium salt, sodium oleoyl sarcosinate, and sodium linoleoyl sarcosinate. In some embodiments, the anionic surfactant is N-lauroyl sarcosine.
[0017] In some embodiments, the polymer dye conjugate has Formula III: [ka] (In the formula, each A is independently selected from the group consisting of aromatic comonomers and heteroaromatic comonomers; each optional M is independently selected from the group consisting of aromatic comonomers, heteroaromatic comonomers, band gap modifying monomers, optionally substituted ethylene, and ethynylene; each optional L is a linker moiety; each G 1 and G 2 are independently selected from an unmodified polymer end and a modified polymer end; a, c, and d define the mol% of each unit, which may each be uniformly or randomly repeated, where each a is from 10 to 100% mol%, each c is from 0 to 90% mol%, and each d is from 0 to 25% mol%; each b is independently 0 or 1; each m is an integer from 1 to about 10,000 The polymeric dye comprises a binding partner conjugated to the polymeric dye having the structure:
[0018] In some embodiments, A comprises a DHP moiety. In some embodiments, A comprises a fluorene moiety. In some embodiments, A comprises a DHP and a fluorene moiety.
[0019] In some embodiments, the polymer dye conjugate has Formula I: [ka] (In the formula, each X is independently C or Si; Each Y is independently a CR 1 R 2 or SiR 1 R 2 and; Each R 1 are independently an ammonium alkyl salt, an ammonium alkyloxy salt, an ammonium oligoether salt, a sulfonate alkyl salt, a sulfonate alkoxy salt, a sulfonate oligoether salt, a sulfonamide oligoether, or a water-solubilizing moiety: [ka] and; Each R 2 is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, PEG group, ammonium alkyl salt, ammonium alkyloxy salt, ammonium oligoether salt, sulfonate alkyl salt, sulfonate alkoxy salt, sulfonate oligoether salt, sulfonamide oligoether, or a water-solubilizing moiety [ka] and; Each R 3 is independently selected from the group consisting of H, alkyl, alkene, alkyne, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, and a PEG group; each Z is independently selected from the group consisting of C, O, and N; Each Q is a bond, NH, or NR 4 and CH2; each subscript n is independently an integer from 0 to 20; Each M is a unit capable of modifying the polymer bandgap and is distributed uniformly or randomly along the polymer backbone; L is a linker; G 1 and G 2 are each independently selected from the group consisting of aryl or heteroaryl substituted with one or more pendant chains terminating in a functional group selected from hydrogen, halogen, alkyne, optionally substituted aryl, optionally substituted heteroaryl, halogen-substituted aryl, silyl, diazonium salt, triflate, acetyloxy, azide, sulfonate, phosphate, boronate-substituted aryl, boronate ester-substituted aryl, boronate ester, boronic acid, optionally substituted dihydrophenanthrene (DHP), optionally substituted fluorene; amine, carbamate, carboxylic acid, carboxylate, maleimide, activated ester, N-hydroxysuccinimidyl, hydrazine, hydrazide, hydrazone, azide, alkyne, aldehyde, thiol, and protecting groups thereof that are conjugated to a binding partner. In some embodiments, L is an aryl or heteroaryl group substituted with one or more pendant chains terminating in functional groups selected from the group consisting of amines, carbamates, carboxylic acids, carboxylates, maleimides, activated esters, N-hydroxysuccinimidyl, hydrazines, hydrazides, hydrazones, azides, alkynes, aldehydes, thiols, and protecting groups thereof, which are conjugated to binding partners, evenly or randomly distributed along the polymer backbone; a, c, and d each define the mol% of each unit within the structure, which may be repeated evenly or randomly, where a is 10 to 100% mol%, c is 0 to 90% mol%, and each d is 0 to 25% mol%; each b is independently 0 or 1; m is an integer from 1 to about 10,000; and each n is independently an integer from 1 to 20.
[0020] The binding partner may be a molecule or molecular complex capable of specifically binding to the target analyte. The binding partner may be a protein, an affinity ligand, an antibody, or an antibody fragment. In some embodiments, the binding partner may be selected from the group consisting of a monoclonal antibody, a polyclonal antibody, an immunoglobulin, an immunologically active portion of an immunoglobulin, a single-chain antibody, a Fab fragment, a Fab' fragment, and a F(ab')2 fragment, and an scFv fragment.
[0021] Compositions are provided that include a polymer-dye conjugate; an aqueous buffer; and a zwitterionic or anionic surfactant. The compositions may include the zwitterionic or anionic surfactant at a concentration below the critical micelle concentration (CMC). In some embodiments, the surfactant may be at a concentration of 0.05 to 0.25% (w / v), 0.06 to 0.20% (w / v), or 0.08 to 0.16% (w / v). The aqueous buffer may include an additional additive selected from the group consisting of a protein stabilizer, a preservative, and an additional surfactant. After exposure to a blood sample and flow cytometry analysis, the composition may demonstrate reduced nonspecific binding of the polymer-dye conjugate to leukocytes in the sample. The reduced nonspecific binding may be compared to the same composition without the zwitterionic or anionic surfactant. The leukocytes may be selected from the group consisting of monocytes and granulocytes. [Brief explanation of the drawings]
[0022] [Figure 1A] FIG. 1A shows plots of fluorescence intensity as a function of wavelength for fluorene (FF), dihydrophenanthrene (DD), and fluorene-DHP (DF) polymeric dyes.
[0023] [Figure 1B]Figure 1B shows a graph of the absorption spectra of fluorene (Fl-Fl) and dihydrophenanthrene (DHP-DHP) polymers. The DHP-DHP polymer (black curve) exhibits lambda max (λmax) at 390 and 410 nm, while the Fl-Fl (gray curve) polymer exhibits lambda max (λmax) at approximately 400 nm.
[0024] [Figure 2] Figure 2 shows flow cytometry dot plots of unstained blood cells (top panel); blood cells stained with a polymeric dye and no surfactant (bottom left panel); and blood cells stained with a composition containing a polymeric dye and surfactant (bottom right). Blood samples were stained using the antibody-free fluorescent polymeric dye SN v605 and analyzed on a flow cytometer. The surfactant-free polymeric dye showed nonspecific binding to monocytes / granulocytes (bottom left). The polymeric dye containing EMPIGEN BB® showed a substantial reduction in nonspecific binding to monocytes / granulocytes (bottom right).
[0025] [Figure 3] Figure 3 shows dot plots of blood cells without polymer dye conjugate (top panel), blood cells stained with SN 605-CD20 conjugate and detergent (bottom left panel), and blood cells stained with SN 605-CD20 conjugate and detergent (bottom right panel). With the use of detergent, the percentage of nonspecifically bound granulocytes decreased (see "P2" gate in the dot plot). Also, the functional profile of the conjugate did not change, as the percentage of positive population was similar in both cases (see "P1" gate in the dot plot).
[0026] [Figure 4]Figure 4 shows a bar graph of median fluorescence intensity (MdFI) values of monocytes in the presence and absence of detergent for two lots of polymer dye conjugate (SN v605-CD20) compared to unstained monocytes (autofluorescence). In the presence of detergent, nonspecific interactions on monocytes were substantially reduced for both Lot 1 and Lot 2 SN605 CD20 conjugates.
[0027] [Figure 5] Figure 5 shows a bar graph of MdFI values of granulocytes in the presence and absence of detergent for two lots of polymer dye conjugate (SN v605-CD20) compared to unstained granulocytes (autofluorescence). In the presence of detergent, nonspecific interactions with granulocytes were reduced for both Lot 1 and Lot 2 SN605 CD20 conjugates.
[0028] [Figure 6] Figure 6 shows dot plots of blood cells without polymer dye conjugate (top left), blood cells stained with SN v786-CD103 conjugate and Empigen BB® surfactant (bottom left), and blood cells stained with SN v786-CD103 conjugate and no surfactant (top right). The dot plots compare one of the claimed polymers to BV786-CD103, a tandem fluorescent dye (bottom right) (available from Becton Dickinson). In the presence of surfactant, the percentage of nonspecifically bound granulocytes and monocytes was reduced (see "P1" and "P2" gates, respectively, in the dot plots).
[0029] [Figure 7]Figure 7 shows a bar graph of MdFI values of monocytes in the presence and absence of detergent for two lots of polymer-dye conjugate (SN v786-CD103) compared to unstained monocytes (autofluorescence). In the presence of detergent, nonspecific binding of the polymer conjugate to monocytes was substantially reduced for both lots of polymer-dye conjugate.
[0030] [Figure 8] Figure 8 shows a bar graph of MdFI values of granulocytes in the presence and absence of surfactant for two lots of polymer conjugate compared to unstained granulocytes (autofluorescence). In the presence of surfactant, nonspecific binding of the polymer conjugate to granulocytes was substantially reduced for both lots of polymer dye conjugate.
[0031] [Figure 9] Figure 9 shows dot plots of blood cells stained with detergent-containing and detergent-free SN v605-CD20 conjugates (top panel), the bottom left panel is the non-ionic detergent Tween®-20, and the bottom right panel is the non-ionic detergent Pluronic F-68. The percentage of non-specifically bound monocytes was not reduced with the non-ionic detergents Tween®-20 and Pluronic F-68 (see the "non-specific monocyte" gate in the dot plot).
[0032] [Figure 10]Figure 10 shows dot plots of blood cells without dye conjugate (upper left panel); blood cells stained with SN v605-CD20 conjugate and containing BSA (upper right panel); blood cells stained with SN v605-CD20 conjugate and containing oxidized BSA (lower left panel); and blood cells stained with SN v605-CD20 conjugate and containing BSA-Cy5-ox (lower right panel). The percentage of nonspecifically bound monocytes and granulocytes was not substantially reduced by the use of protein blockers (see "P1" gate in the dot plots).
[0033] [Figure 11-1] Figure 11 shows three graphs showing the effect of detergent concentration on monocyte negative counts (MFI) for unstained and stained Donor 1 (D1) and Donor 2 (D2) blood samples for SN v428 CD19 (Figure 11, top panel), SN v428 CD22 (Figure 11, bottom panel), and SN v428 CD25 (Figure 11, middle panel) specificities, respectively. SN conjugates demonstrated lower nonspecific monocyte interactions in the presence of 0.06 to 0.20% Empigen BB® than in the absence of detergent.
[0034] [Figure 11-2] Figure 11 (continued) shows three graphs showing the effect of detergent concentration on monocyte negative counts (MFI) for Donor 1 (D1) and Donor 2 (D2) blood samples for unstained and stained samples for SN v428 CD19 (Figure 11, top panel), SN v428 CD22 (Figure 11, bottom panel), and SN v428 CD25 (Figure 11, middle panel), respectively; data are presented as % of negative monocyte MFI in the absence of Empigen BB® samples. Samples stained with BD polymer dye conjugates showed a lower percent of nonspecific monocyte interactions in the presence of 0.06 to 0.20% Empigen BB® than in the absence of detergent.
[0035] [Figure 12]Figure 12 (nine graphs) shows the effect of surfactant concentration on negative granulocytes (top three panels), positive lymphocytes (middle panel), and % positive lymphocytes without Empigen BB® samples (bottom three panels). Unstained and stained blood samples from Donor 1 (D1) and Donor 2 (D2) are shown. For the CD19 BD, CD25 BD, and CD22 BD polymer dye conjugates, respectively, negative interactions with granulocytes were slightly lower in the presence of 0.06 to 0.20% surfactant compared to the absence of surfactant (top three panels). For the CD19 BD, CD25 BD, and CD22 BD polymer dye conjugates, respectively, positive lymphocyte data were similar or slightly higher in the presence of surfactant compared to the absence of surfactant (middle three and bottom three panels).
[0036] [Figure 13] FIG. 13 shows dot plots of the SS / FL9 staining patterns of donor 1 (top panel) and donor 2 (bottom panel) blood samples for SN v428 CD19 Lot No. D19-094 polymer dye conjugate at 0.5 μg / test with no surfactant, 0.06%, 0.12%, and 0.2% Empigen BB® surfactant, and CD19 BV-421 conjugate (Becton Dickinson) at its commercial dose.
[0037] [Figure 14] FIG. 14 shows dot plots of the SS / FL9 staining patterns of donor 1 (top panel) and donor 2 (bottom panel) blood samples for SN v428 CD25 Lot No. D19-107 polymer dye conjugate at 0.5 μg / test with no surfactant, 0.06%, 0.12%, and 0.2% surfactant, and CD25 BV-421 conjugate (Becton Dickinson) at its commercial dose.
[0038] [Figure 15]FIG. 15 shows dot plots of donor 1 (top panel) and donor 2 (bottom panel) blood samples for SN v428 CD22 Lot No. D19-109 polymer dye conjugate at 0.5 μg / test with no surfactant, 0.06%, 0.12%, and 0.2% surfactant, and CD22 BV-421 conjugate (Becton Dickinson) at its commercial dose.
[0039] [Figure 16] Figure 16 shows a dot plot containing the percentage of dead cells at up to 0.2% detergent. CD19-SNv428D19-094 without EMPIGEN BB® (negative control) and with 0.06%, 0.12%, and 0.2% EMPIGEN BB® was tested on whole blood samples from donor 1 and donor 4 stained with 7-AAD to assess the percentage of dead cells in each condition. A whole blood sample stored for more than 24 hours was added as a positive control for 7-AAD staining (left panel, 12% dead cells). The percentage of dead cells was not substantially increased by the presence of up to 0.2% EMPIGEN BB® when compared to samples without detergent.
[0040] [Figure 17A] FIG. 17A shows a dot plot of a peripheral blood sample without single-color conjugate, clearly showing the absence of a population in the CD20+ gate.
[0041] [Figure 17B]Figure 17B shows a positive control dot plot of a peripheral blood sample in the presence of CD20-SN v605 single-color conjugate in a buffer composition containing BSA, sodium azide, Pluronic™ F-68 (PF-68), and Empigen BB® as additives. When compared to the negative control dot plot (Figure 17C), the % populations in the "monocyte non-specific binding" and "granulocyte non-specific binding" gates were significantly reduced, demonstrating the effectiveness of Empigen BB® in removing or reducing non-specific binding to monocytes and granulocytes, respectively.
[0042] [Figure 17C] FIG. 17C shows a negative control dot plot of peripheral blood samples in the presence of CD20-SN v605 monochromatic conjugate in a buffer composition containing only BSA, PF-68, and sodium azide as additives.
[0043] [Figure 17D] FIG. 17D shows the test point plot of peripheral blood samples in the presence of CD20-SN v605 monochromatic conjugate in a buffer composition containing BSA, sodium azide, PF-68, and NLS (0.16% w / v) as additives.
[0044] [Figure 17E] FIG. 17E shows the test point plot of peripheral blood samples in the presence of CD20-SN v605 monochromatic conjugate in a buffer composition containing BSA, sodium azide, PF-68, and NLS (0.08% w / v) as additives. DETAILED DESCRIPTION OF THE INVENTION
[0045] Detailed Description of the Disclosure Reference will now be made in detail to certain embodiments of the disclosed subject matter, examples of which are illustrated in part in the accompanying drawings and examples. While the disclosed subject matter will be described in conjunction with the recited claims, it will be understood that the exemplified subject matter is not intended to limit the claims to the disclosed subject matter. General Disclosure
[0046] The present disclosure generally relates to compositions and methods for detecting an analyte in a sample using a composition comprising at least one surfactant and at least one polymeric dye conjugated to a binding partner (e.g., an antibody), e.g., a fluorescent polymeric dye conjugated to a binding partner. More specifically, the present disclosure relates to a method for reducing or eliminating non-specific binding of at least one polymeric dye conjugate in a biological sample, e.g., a blood sample, comprising contacting the at least one polymeric dye conjugate with at least one zwitterionic or anionic surfactant before, during, or after contacting the polymeric dye conjugate with the biological sample, e.g., a blood sample, wherein the contacting results in reduced non-specific binding of the at least one polymeric dye conjugate to cells, e.g., white blood cells in the blood sample. The surfactant may be added to the blood sample before contacting. The surfactant may be added to the polymeric dye conjugate before contacting with the biological sample. definition
[0047] The abbreviations used herein have their conventional meaning within the chemical and biological arts.
[0048] The singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.
[0049] The term "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items. Unless otherwise specified, the phrase "room temperature" refers to 18 to 27°C.
[0050] Unless otherwise specified, the term "percent" or "%" refers to percent by weight.
[0051] All patents, patent applications, and publications mentioned herein are incorporated by reference in their entirety.
[0052] The term "analyte" refers to a molecule, compound, or other component in a sample. Analytes can include, but are not limited to, peptides, proteins, polynucleotides, organic molecules, sugars and other carbohydrates, and lipids.
[0053] The term "binding partner" refers to a molecule that can specifically bind to an analyte. A binding partner can be any of several different types of molecule, including an antibody or antigen-binding fragment thereof or other protein, peptide, polysaccharide, lipid, nucleic acid or nucleic acid analog, such as an oligonucleotide, aptamer, or PNA (peptide nucleic acid).
[0054] The term "CD" refers to Cluster of differentiation.
[0055] The term "compensation" in flow cytometry refers to the mathematical process of correcting for fluorescent spillover (spectral overlap in multiparameter flow cytometry data). For example, compensation may be performed by removing the signal of any given fluorochrome from all detectors except those specialized for measuring that dye. Because fluorochromes can have wide spectral ranges, they can overlap, resulting in undesirable confusion during data analysis.
[0056] The term "labeled binding partner" refers to a binding partner conjugated to a dye. The term "reaction solution" refers to a solution containing a labeled binding partner. In some embodiments, in addition to the labeled binding partner, the reaction solution may further include stabilizers, salts, buffers, surfactants, and / or other reagents.
[0057] The term "linker" or "linkage" refers to a connecting moiety that connects two groups and has a backbone of 100 or less atoms in length. The linker or linkage can be a covalent bond connecting two groups or a chain of between 1 and 100 atoms in length, for example, a chain of 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, or more carbon atoms in length, and the linker can be linear, branched, cyclic, or a single atom. In some embodiments, the linker is a branched linker, which refers to a connecting moiety that connects three or more groups. In certain cases, one, two, three, four, five, or more carbon atoms in the linker backbone can be optionally substituted with sulfur, nitrogen, or oxygen heteroatoms. In some embodiments, the linker backbone includes a binding functional group, such as an ether, thioether, amino, amide, sulfonamide, carbamate, thiocarbamate, urea, thiourea, ester, thioester, or imine. The bonds between backbone atoms can be saturated or unsaturated, and in some cases, no more than one, two, or three unsaturated bonds are present in the linker backbone. The linker can include, for example, one or more substituents with alkyl, aryl, or alkenyl groups. The linker can include, but is not limited to, polyethylene glycol, ether, thioether, tertiary amine, linear or branched alkyl, such as methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), and the like. The linker backbone can be a cyclic group, such as an aryl, heterocyclic, or cycloalkyl group, where two or more atoms of the cyclic group, for example, two, three, or four atoms, are contained within the backbone. The linker may be cleavable or non-cleavable.
[0058] The linker moiety may be attached to "A" as taught in U.S. Published Application No. 2020 / 0190253A1, which is incorporated herein by reference in its entirety, or to "L" as taught in U.S. Published Application No. 2019 / 0144601, which is incorporated herein by reference in its entirety. The linker moiety may comprise a sulfonamide, disulfonamide, selenamide, sulfinamide, sultam, disulfinamide, amide, seleninamide, phosphonamide, phosphinamide, phosphonamidate, or secondary amine.
[0059] As described therein, each relative to a linker moiety, the term "sulfonamide" refers to a -S(O)NR- moiety; the term "disulfonamide" refers to a -S(O)NRS(O)- moiety; the term "selenoneamide" refers to a -Se(O)NR- moiety; the term "sulfinamide" refers to a -S(O)NR- moiety; the term "disulfinamide" refers to a -S(O)NRS(O)- moiety; and the term "seleninamide" refers to a The term "Se(O)NR-" refers to the moiety; the term "phosphonamide" refers to the moiety -NR-PR(O)NR-; the term "phosphinamide" refers to the moiety -PR(O)NR-; the term "phosphonamidate" refers to the moiety -O-PR(O)NR-; the term "sultam" refers to cyclic sulfonamides (where, for example, the R group is attached to the sulfur atom via an alkylene moiety); for each term, the R group is independently H, alkyl, haloalkyl, or aryl.
[0060] The term "terminal" as used herein refers to the end of a conjugate polymer chain, which may contain a functional group that provides bioconjugation. In some cases, such functional groups are referred to as terminal linkers. The terminal may be, for example, an aryl or heteroaryl substituted with one or more pendant chains terminating in a functional group selected from hydrogen, halogen, alkyne, optionally substituted aryl, optionally substituted heteroaryl, halogen-substituted aryl, silyl, diazonium salt, triflate, acetyloxy, azide, sulfonate, phosphate, boronate-substituted aryl, boronate ester-substituted aryl, boronate ester, boronic acid, optionally substituted tetrahydropyrene (THP), optionally substituted fluorene, optionally substituted dihydrophenanthrene (DHP); amine, carbamate, carboxylic acid, carboxylate, maleimide, activated ester, N-hydroxysuccinimidyl, hydrazine, hydrazide, hydrazone, azide, alkyne, aldehyde, thiol, and their protecting groups for conjugation to substrates or binders.
[0061] The term "MdFI" or "MDFI" refers to median fluorescence intensity.
[0062] The term "% recruitment" refers to the number of gated cells in the appropriate population.
[0063] The term "multiplex" as used herein refers to an assay or other analytical method that is capable of assaying multiple analytes simultaneously.
[0064] The term "PEG" refers to polyethylene glycol or poly(ethylene glycol). The number after "PEG" refers to the average molecular weight, where Mw refers to the weight average molecular weight and Mn refers to the number average molecular weight.
[0065] The term "PBS" refers to phosphate-buffered saline, an aqueous buffer that may contain sodium chloride, disodium hydrogen phosphate, potassium chloride, and potassium dihydrogen phosphate. For example, PBS may contain milliQ water or deionized water, 137 mM NaCl, 2.7 mM KCl, 10 mM NaHPO, and 1.8 mM KHPO. The pH may be approximately pH 7.0-7.4. PBS may or may not be stored with an azide, such as sodium azide. PBS is an isotonic solution.
[0066] The acronym "SSC" refers to side scatter.
[0067] The acronym "WBC" refers to white blood cells.
[0068] A "dye" is a moiety that provides a detectable signal and may be directly or indirectly attached to or incorporated into a binding partner. Dyes used in the present disclosure may be colored, fluorescent, or luminescent and are typically detected by a detector in a flow cytometer, such as a PMT or APD. Fluorescent dyes may be monomeric or polymeric. Fluorescent dyes may be fluorescent polymeric dyes. Polymeric dyes are particularly useful for analyzing chemical and biological targets. Because they contain multiple chromophores, they are highly responsive optical reporters and efficient light absorbers. Suitable fluorescent polymeric dyes for use in the present disclosure are described herein, for example, in US 2019 / 0144601 and US 2020 / 0190253. Examples of polymeric dyes include, but are not limited to, conjugated polymers with repeating chromophore units, aggregates of conjugated molecules, luminescent dyes attached via side chains to saturated polymers, semiconductor quantum dots, and dendritic structures. The polymeric and monomeric dyes disclosed in US Pat. Nos. 7,214,489, 8,354,239 and 8,575,303 may also be used in the present invention.
[0069] As used herein, the term "ammonium" refers to a compound of the formula NHR3 + wherein each R group is independently hydrogen or a substituted or unsubstituted alkyl, aryl, aralkyl, or alkoxy group. Preferably, each R group is hydrogen.
[0070] As used herein, "oligoether" is understood to mean an oligomer containing structural repeat units having ether functionality. As used herein, "oligomer" is understood to mean a molecule containing one or more identifiable structural repeat units of the same or different formula.
[0071] The term "sulfonate functional group" or "sulfonate," as used herein, refers to both the free sulfonate anion (-S(=O)2O-) and its salts. Thus, the term sulfonate encompasses sulfonate salts, such as sodium sulfonate, lithium sulfonate, potassium sulfonate, and ammonium sulfonate.
[0072] The term "sulfonamide," as used herein, refers to a group of formula -SO2NR-, where R is hydrogen, alkyl, or aryl.
[0073] The term "alkyl," as used herein, refers to a straight-chain or branched saturated aliphatic radical having the indicated number of carbon atoms. For example, C1-C6 alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, and the like. Other alkyl groups include, but are not limited to, heptyl, octyl, nonyl, decyl, and the like. Alkyl may contain any number of carbons, for example, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4-6, and 5-6. Alkyl groups are typically monovalent but may be divalent, for example, when the alkyl group links two moieties together.
[0074] The term "cycloalkyl," as used herein, refers to a saturated or partially unsaturated monocyclic, fused bicyclic, or bridged polycyclic ring assembly containing 3 to 12 ring atoms, or monocyclic rings where the number of atoms is indicated include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Bicyclic and polycyclic rings include, for example, norbornane, decahydronaphthalene, and adamantane. For example, C 3~8 Cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, and norbornane.
[0075] The term "haloalkyl" as used herein refers to an alkyl, as defined above, in which some or all of the hydrogen atoms have been replaced with halogen atoms. Halogen (halo) preferably represents chloro or fluoro, but may also be bromo or iodo. For example, haloalkyl includes trifluoromethyl, fluoromethyl, 1,2,3,4,5-pentafluorophenyl, etc. The term "perfluoro" defines a compound or radical in which at least two available hydrogen atoms have been replaced with fluorine. For example, perfluorophenyl refers to 1,2,3,4,5-pentafluorophenyl, perfluoromethane refers to 1,1,1-trifluoromethyl, and perfluoromethoxy refers to 1,1,1-trifluoromethoxy.
[0076] As used herein, the term "halogen" refers to fluorine, chlorine, bromine, and iodine.
[0077] The term "alkoxy," as used herein, refers to an alkyl group, as defined above, with an oxygen atom connecting the alkyl group to its point of attachment. Examples of alkoxy groups include methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, and the like. Alkoxy groups may be further substituted with various substituents described herein. For example, alkoxy groups may be substituted with halogens to form "halo-alkoxy" groups.
[0078] The term "alkene," as used herein, refers to a straight-chain or branched hydrocarbon having at least one double bond. Examples of alkene groups include, but are not limited to, vinyl, propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5-hexatrienyl. Alkene groups are typically monovalent but may be divalent, for example, when an alkenyl group links two moieties together.
[0079] The term "alkyne," as used herein, refers to a straight-chain or branched hydrocarbon having at least one triple bond. Examples of alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, isobutynyl, sec-butynyl, butadiynyl, 1-pentynyl, 2-pentynyl, isopentynyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,3-hexadiynyl, 1,4-hexadiynyl, 1,5-hexadiynyl, 2,4-hexadiynyl, or 1,3,5-hexatriynyl. Alkynyl groups are typically monovalent but may be divalent, for example, when the alkynyl group links two moieties together.
[0080] The term "aryl," as used herein, refers to a monocyclic or fused bicyclic, tricyclic, or higher-cyclic aromatic ring assembly containing 6 to 16 ring carbon atoms. For example, aryl can be phenyl, benzyl, or naphthyl, preferably phenyl. "Arylene" refers to a divalent radical derived from an aryl group. The aryl group can be mono-, di-, or trisubstituted by one, two, or three radicals selected from alkyl, alkoxy, aryl, hydroxy, halogen, cyano, amino, amino-alkyl, trifluoromethyl, alkylenedioxy, and oxy-C2-C3-alkylene; all of which are optionally further substituted, for example, as defined above; or 1- or 2-naphthyl; or 1- or 2-phenanthrenyl. Alkylenedioxy is a divalent substituent attached to two adjacent carbon atoms of phenyl, such as methylenedioxy or ethylenedioxy. Oxy-C2-C3-alkylene is also a divalent substituent attached to two adjacent carbon atoms of phenyl, such as oxyethylene or oxypropylene. An example of oxy-C2-C3-alkylene-phenyl is 2,3-dihydrobenzofuran-5-yl.
[0081] Preferred as aryl is naphthyl, phenyl or phenyl mono- or di-substituted by alkoxy, phenyl, halogen, alkyl or trifluoromethyl, especially phenyl or phenyl mono- or di-substituted by alkoxy, halogen or trifluoromethyl, especially phenyl.
[0082] The term "aryloxy" as used herein refers to an O-aryl group, where aryl is as defined above. An aryloxy group can be unsubstituted or substituted with one or two suitable substituents. The term "phenoxy" refers to an aryloxy group in which the aryl moiety is a phenyl ring. The term "heteroaryloxy" as used herein means an -O-heteroaryl group, where heteroaryl is as defined below. The term "(hetero)aryloxy" is used to indicate that the moiety is an aryloxy or heteroaryloxy group.
[0083] The term "polyethylene glycol" or "PEG" as used herein refers to a compound of the formula -(CH2-CH2-O-) n " refers to a family of biocompatible, water-soluble linear polymers based on ethylene glycol monomer units described by the formula: - or derivatives thereof. In some embodiments, "n" is 1000 or less, 500 or less, 200 or less, 100 or less, 50 or less, 40 or less, 30 or less, 20 or less, 15 or less, e.g., 3 to 15, or 10 to 15. It is understood that the PEG polymer group may be of any convenient length and may contain a variety of end groups and / or additional substituents, including, but not limited to, alkyl, aryl, hydroxyl, amino, acyl, carboxylic acid, carboxylate ester, acyloxy, and amide end groups and / or substituents.
[0084] The term "heteroaryl" as used herein refers to a monocyclic or fused bicyclic or tricyclic aromatic ring assembly containing 5 to 16 ring atoms, in which 1 to 4 of the ring atoms are heteroatoms such as N, O, or S. For example, heteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzothienyl, benzofuranyl, furanyl, pyrrolyl, thiazolyl, benzothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, or any other radical substituted, for example, by alkyl, nitro, or halogen, especially mono- or di-substituted. Pyridyl represents 2-, 3-, or 4-pyridyl, advantageously 2- or 3-pyridyl. Thienyl represents 2- or 3-thienyl. Quinolinyl preferably represents 2-, 3-, or 4-quinolinyl. Isoquinolinyl preferably represents 1-, 3-, or 4-isoquinolinyl. Benzopyranyl and benzothiopyranyl preferably represent 3-benzopyranyl or 3-benzothiopyranyl, respectively. Thiazolyl preferably represents 2- or 4-thiazolyl, most preferably 4-thiazolyl. Triazolyl is preferably 1-, 2-, or 5-(1,2,4-triazolyl). Tetrazolyl is preferably 5-tetrazolyl.
[0085] Preferably, heteroaryl is pyridyl, indolyl, quinolinyl, pyrrolyl, thiazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, furanyl, benzothiazolyl, benzofuranyl, isoquinolinyl, benzothienyl, oxazolyl, indazolyl, or any of the substituted, especially mono- or disubstituted, radicals.
[0086] Similarly, substituents for the aryl and heteroaryl groups are varied and include, in a number ranging from zero to the total number of open valences on the aromatic ring system, -halogen, -OR', -OC(O)R', -NR'R", -SR', -R', -CN, -NO2, -CO2R', -CONR'R", -C(O)R', -OC(O)NR'R", -NR"C(O)R', -NR"C(O)2R', -NR'-C(O)NR"R''', -NH-C(NH2)=NH, -NR'C(NH2)=NH, -NH-C(NH2)=NR', -S(O)R', -S(O) R', -S(O)NR'R", -N, -CH(Ph), perfluoro(C-C)alkoxy, and perfluoro(C-C)alkyl; where R', R", and R''' are independently selected from hydrogen, (C-C)alkyl and heteroalkyl, unsubstituted aryl and heteroaryl, (unsubstituted aryl)-(C-C)alkyl, and (unsubstituted aryl)oxy-(C-C)alkyl.
[0087] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring have the formula -TC(O)-(CH2) q and optionally substituted with a substituent of formula -U-, where T and U are independently -NH-, -O-, -CH2-, or a single bond, and q is an integer from 0 to 2. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring are of formula -A-(CH2) r wherein A and B are independently -CH2-, -O-, -NH-, -S-, -S(O)-, -S(O)2-, -S(O)2NR'-, or a single bond, and r is an integer from 1 to 3. One of the single bonds in the new ring thus formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms in the aryl or heteroaryl ring may be a group of the formula -(CH2) s -X-(CH2) twhere s and t are independently integers from 0 to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O)2-, or -S(O)2NR'-. The substituent R' in -NR'- and -S(O)2NR'- is selected from hydrogen or unsubstituted (C1-C6) alkyl.
[0088] The term "(hetero)arylamino," as used herein, refers to an amine radical substituted with an aryl group (e.g., -NH-aryl). An arylamino may also be an aryl radical substituted with an amine group (e.g., -aryl-NH). An arylamino may be substituted or unsubstituted.
[0089] The term "amine," as used herein, refers to an alkyl group, as defined herein, having one or more amino groups. The amino groups may be primary, secondary, or tertiary. The alkylamine may be further substituted with a hydroxy group. Amines useful in the present invention include, but are not limited to, ethylamine, propylamine, isopropylamine, ethylenediamine, and ethanolamine. The amino group may be attached to the point of attachment of the alkylamine to the rest of the compound, may be in the omega position of the alkyl group, or may be attached together with at least two carbon atoms of the alkyl group. One skilled in the art will recognize that other alkylamines are useful in the present invention.
[0090] The term "carbamate," as used herein, refers to a functional group having the structure -NR"COR', where R' and R" are independently selected from hydrogen, (C1-C8) alkyl and heteroalkyl, unsubstituted aryl and heteroaryl, (unsubstituted aryl)-(C1-C4) alkyl, and (unsubstituted aryl)oxy-(C1-C4) alkyl. Examples of carbamates include t-Boc, Fmoc, benzyloxy-carbonyl, alloc, methyl carbamate, ethyl carbamate, 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluorenylmethyl carbamate, Tbfmoc, Climoc, Bimoc, DBD-Tmoc, Bsmoc, Troc, Teoc, 2-phenylethyl carbamate, Adpoc, 2-chloroethyl carbamate, 1,1-dimethyl-2-haloethyl carbamate, DB-t-BOC, TCBOC, Bpoc, t-Bumeoc, Pyoc, Bnpeoc, V-(2-pivaloylamino)-1,1-dimethylethyl carbamate, and NpSSPeoc.
[0091] The term "carboxylate," as used herein, refers to the conjugate base of a carboxylic acid and can generally be represented by the formula RCOO. For example, the term "magnesium carboxylate" refers to the magnesium salt of a carboxylic acid.
[0092] The term "activated ester" as used herein refers to a carboxyl-activating group used in peptide chemistry to facilitate the condensation of the carboxyl group with the free amino group of an amino acid derivative. Descriptions of these carboxyl-activating groups can be found in general textbooks of peptide chemistry; for example, KD Kopple, "Peptides and Amino Acids", W.A. Benjamin, Inc., New York, 1966, pp. 50-51, and E. Schroder and K. Lubke, "The Peptides"; Vol. 1, Academic Press, New York, 1965, pp. 77-128.
[0093] The terms "hydrazine" and "hydrazide" refer to compounds containing a single-bonded nitrogen, one of which is a primary amine functional group.
[0094] The term "aldehyde," as used herein, refers to a chemical compound having a --CHO group.
[0095] The term "thiol," as used herein, refers to a compound containing a functional group composed of a sulfur-hydrogen bond. The general chemical structure of a thiol functional group is R-SH, where R represents an alkyl, alkene, aryl, or other carbon-containing group.
[0096] The term "silyl" as used herein means Si(R z ) 3, wherein each R z is independently alkyl, aryl, or other carbon-containing group.
[0097] The term "diazonium salt" as used herein refers to a diazonium salt of R-N2 + X - where R can be any organic residue (e.g., alkyl or aryl) and X is an inorganic or organic anion (e.g., a halogen).
[0098] The term "triflate," also known as trifluoromethanesulfonate, is a group having the formula CF3SO3.
[0099] The term "boronic acid," as used herein, refers to the structure -B(OH). Those skilled in the art will recognize that boronic acids may be present as boronate esters at various stages in the synthesis of a quencher. Boronic acid is meant to include such esters. The terms "boronic acid ester" or "boronate ester," as used herein, refer to -B(Z 1 )(Z 2 ) moiety, wherein Z1 and Z 2 together form a moiety, and the atom bonded to the boron is an oxygen atom in each case. The boronic ester moiety may be a five-membered ring. The boronic ester moiety may be a six-membered ring. The boronic ester moiety may be a mixture of five- and six-membered rings.
[0100] Values expressed in range format should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also all individual numerical values or subranges subsumed within that range, as if each numerical value and subrange were explicitly recited. For example, the range "about 0.1% to about 5%" or "about 0.1% to 5%" should be interpreted to include not only about 0.1% to about 5%, but also individual values (e.g., 1%, 2%, 3%, and 4%) and subranges (e.g., 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the recited range. The phrase "about X to Y" has the same meaning as "about X to about Y" unless otherwise indicated. Similarly, the phrase "about X, Y, or about Z" has the same meaning as "about X, about Y, or about Z" unless otherwise indicated.
[0101] As used herein, "dye conjugate" refers to a binding partner that is conjugated to a non-polymeric or polymeric dye.
[0102] As used herein, "SN" refers to "Super Nova" dyes commercially available from Beckman Coulter, Inc.
[0103] As used herein, "EMPIGEN BB®" refers to a zwitterionic surfactant comprising N,N-dimethyl-N-dodecylglycine betaine (CAS No. 66455-29-6) at a betaine concentration of about 30% in aqueous solution.
[0104] The term "about," as used herein, can allow for a degree of variation in a value or range, for example, within 10%, within 5%, or within 1% of a stated value or of a stated range limit.
[0105] As used herein, "specific binding" refers to the binding of an antibody or other binding partner (e.g., in a polymer-conjugated dye) to an epitope of a cell or target analyte targeted by the antibody or binding partner.
[0106] As used herein, "non-specific binding" refers to the binding of an antibody or other binding partner (e.g., in a polymer-conjugated dye) to cells or sample components that do not contain the epitope targeted by the antibody or other binding partner. For example, non-specific binding occurs when an antibody binds to a cell that does not have an epitope specific for that antibody.
[0107] As used herein, "reducing" or "eliminating" nonspecific binding of a polymer-dye conjugate can refer to a reduction in the mean fluorescence intensity (MFI) of "negative" (e.g., negative granulocyte, monocyte, and lymphocyte populations) by at least about 50% (e.g., at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least 99%, or more; about 50% to about 95%, about 50% to about 75%, about 60% to about 80%, or about 65% to about 90%), as compared to when no surfactant is used. In other words, the percent reduction in at least one of background staining of monocytes, granulocytes, and lymphocytes is at least about 50% (e.g., at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least 99%, or more; about 50% to about 95%, about 50% to about 75%, about 60% to about 80%, or about 65% to about 90%) compared to the percent reduction when no surfactant is used.
[0108] The terms "substantial" or "substantially," as used herein, refer to a majority or majority, such as at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more.
[0109] The terms "substantially free" or "substantially free," as used herein, refer to less than about 1%, less than 0.5%, less than 0.1%, less than 0.05%, less than 0.001%, or at less than about 0.0005% or less, about 0%, below the limit of quantitation, below the limit of detectability, or 0%.
[0110] In this document, the terms "a," "an," or "the" are used to include one or more than one unless the context clearly dictates otherwise. The term "or" is used to refer to a non-exclusive "or" unless otherwise indicated. Furthermore, it should be understood that any phraseology or terminology used herein, and that not specifically defined, is for purposes of description only and not limitation. Any use of section headings is intended to facilitate reading of this document and should not be construed as limiting. Furthermore, information associated with a section heading may be found within or outside of that particular section. Furthermore, all publications, patents, and patent documents mentioned in this document are incorporated herein by reference in their entirety, as if individually incorporated by reference. In the event of a conflict in usage between this document and a document so incorporated by reference, the usage in the incorporated reference should be considered supplementary to that of this document; in the event of an irresolvable conflict, the usage in this document will control.
[0111] In certain embodiments, a dye composition is provided that includes at least one polymeric dye conjugate and at least one suitable zwitterionic surfactant.
[0112] In certain embodiments, a dye composition is provided that includes at least one polymeric dye conjugate and at least one suitable anionic surfactant.
[0113] In some embodiments, a method for reducing or eliminating nonspecific binding of at least one polymeric dye conjugate to cells in a biological sample, such as a blood sample, is provided, comprising contacting the at least one polymeric dye conjugate with at least one zwitterionic and / or anionic surfactant before, during, and / or after contacting the at least one polymeric dye conjugate with the biological sample. Steps may be performed in any order without departing from the principles of the invention, unless a temporal or operational order is explicitly recited. Furthermore, certain steps may be performed simultaneously unless explicitly stated as being performed separately in clear claim language. For example, a claimed step of performing X and a claimed step of performing Y may be performed simultaneously in a single operation, and the resulting process would fall within the literal scope of the claimed process. Thus, in some cases, the at least one polymeric dye conjugate may be contacted with at least one zwitterionic or anionic surfactant before contacting the at least one polymeric dye conjugate with a blood sample. In some cases, the at least one polymer-dye conjugate may be contacted with the at least one zwitterionic or anionic surfactant simultaneously with contacting the at least one polymer-dye conjugate with the blood sample. surfactants
[0114] Various types of surfactants were investigated to reduce or prevent non-specific interactions between the polymer dye conjugates and biological samples.
[0115] Suitable surfactants may be zwitterionic surfactants or certain anionic surfactants. Examples of suitable surfactants include those of the general formula
[0116] R 1’ [CO-X(CH2) j ] g -[N + (R 2’ )(R 3’ )] k -(CH2) f -[CH(OH)CH2] h -Y - (In the formula, R 1’ is saturated or unsaturated C 5~24 Alkyl, e.g., C 6~22 , C 5~21 , C 7~19 , C 11~17 , or C 8~18 Alkyl, saturated C 10~16 Alkyl, or saturated C 12~14 alkyl; X is NH, NR 4 ', where R 4’ is C 1~4 alkyl, O, or S; j is an integer from 1 to 10, for example, 2 to 5 and 3; g is 0 or 1, and R 2’ and R 3’ are each independently 1~4 alkyl, e.g., ethyl or methyl; hydroxy is optionally substituted with a hydroxyethyl group or methyl; k is 0 or 1; f is an integer from 0 to 4, e.g., 0, 1, 2, 3, or 4; h is 0 or 1; Y is COO, SO, OPO(OR 5’ )O, or P(O)(OR 5’ )O, where R 5’ is H or C 1~4When k=0, the surfactant may be in its acid form or its sodium or potassium salt.
[0117] The surfactant may be present in a buffer or other suitable aqueous composition according to the present disclosure at a concentration ranging from about 0.05% to about 0.25%, from about 0.06% to about 0.2%, or from about 0.08% to about 0.16% (w / v).
[0118] Suitable zwitterionic surfactants that may be used in accordance with the methods described herein include betaine zwitterionic surfactants, such as alkylbetaines, alkylamidobetaines, amidazolinium betaines, sulfobetaines (INCI Sultaines), and phosphobetaines.
[0119] Examples of suitable zwitterionic surfactants include alkyl betaines, such as those of the formula: R 1’ -N + (CH3)2-CH2COO - ; R 1’ -CO-NH(CH2)3-N + (CH3)2-CH2COO - ; R 1’ -N + (CH3)2-CH2CH(OH)CH2SO3 - ; and R 1’ -CO-NH-(CH2)3-N + (CH3)2-CH2CH(OH)CH2SO3 - There are some.
[0120] Examples of suitable betaines and sulfobetaines are (designated according to INCI): almondamidopropyl betaine, apricotamidopropyl betaine, avocadoamidopropyl betaine, babassuamidopropyl betaine, behenamidopropyl betaine, behenyl betaine, canolamidopropyl betaine, capryl / capramidopropyl betaine, carnitine, cetyl betaine, cocamidoethyl betaine, cocamidopropyl betaine, cocamidopropyl hydroxysultaine, coco betaine, coco hydroxysultaine, coco / oleamidopropyl betaine, coco sultaine, decyl betaine, dihydroxyethyl oleyl glycinate, dihydroxyethyl soybean glycinate, dihydroxyethyl stearyl glycinate, dihydroxyethyl tallow glycinate, dimethicone propyl of PG-betaine, dolucamidopropyl hydroxysultaine, hydrogenated tallow betaine, isostearamidopropyl betaine. betaine, lauramidopropyl betaine, lauryl betaine, lauryl hydroxysultaine, lauryl sultaine, milkamidopropyl betaine, milkamidopropyl betaine, myristamidopropyl betaine, myristyl betaine, oleamidopropyl betaine, oleamidopropyl hydroxysultaine, oleyl betaine, oliamidopropyl betaine, palmamidopropyl betaine, palmitamidopropyl betaine, palmitoyl carnitine, palm kernelamidopropyl betaine, polytetrafluoroethylene acetoxypropyl betaine, ricinoleamidopropyl betaine, sesamidopropyl betaine, soyamidopropyl betaine, stearamidopropyl betaine, stearyl betaine, tallowamidopropyl betaine, tallowamidopropyl hydroxysultaine, tallow betaine, tallow dihydroxyethyl betaine, undecylenamidopropyl betaine and wheat germamidopropyl betaine.
[0121] Suitable betaine zwitterionic surfactants are N-(alkyl C 10~16 )-N,N-dimethylglycine betaine, N-(alkyl C 12~14The glycerin may be N,N-dimethylglycine betaine, N,N-dimethyl-N-dodecylglycine betaine, lauryl dimethyl betaine (also known as lauryl betaine), myristyl sulfobetaine, or n-hexadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate. Lauryl betaine is commercially available as EMPIGEN BB® (Huntsman Corporation) and has a CMC (20-25°C) of 1.6-2.1 mM. Myristyl sulfobetaine (n-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, also known as DMMA) is available under the trade name ZWITTERGENT® 3-14 (Merck KGaA, Darmstadt, Germany) and has a CMC of 100-400 μM. n-Hexadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (also known as 3-N,N-dimethylpalmitylammonio)propanesulfonate, DMPA, is available under the trade name ZWITTERGENT® 3-16 and has a CMC of 10-60 μM. For example, coconut dimethyl betaine is commercially available from Seppic under the trade name AMONYL265®; lauryl betaine is commercially available from Sigma-Aldrich under the trade name EMPIGEN BB®. A further example of a betaine is lauryl-imino-dipropionate, commercially available from Rhodia under the trade name MIRATAINE HC-HA®.
[0122] Zwitterionic surfactants may be present in a buffer or other suitable aqueous composition according to the present disclosure in a range of from about 0.06% to about 0.2%, or from about 0.08% to about 0.16%.
[0123] Examples of suitable anionic surfactants include sarcosinate surfactants in acidic or neutral form. For example, a suitable anionic surfactant may be a sarcosinate surfactant in neutral form. The sarcosinate surfactant may be an alkanoyl sarcosinate surfactant.
[0124] Examples of suitable anionic surfactants include those of the general formula R 1’ [CO-X(CH2) j ] g -(CH2) f -[CH(OH)CH2] h -Y - (In the formula, R 1’ is saturated or unsaturated C 5~24 Alkyl, e.g., C 8~18 Alkyl, saturated C 10~16 Alkyl, or saturated C 12~14 alkyl; X is NH, NR 4 ', where R 4’ is C 1~4 alkyl, O, or S; j is an integer from 1 to 10, for example, 2 to 5 and 3; g is 0 or 1; f is an integer from 0 to 4, for example, 0, 1, 2, 3, or 4; h is 0 or 1; Y is COO, SO3, OPO(OR 5’ )O, or P(O)(OR 5’ )O, where R 5’ is H or C 1~4 alkyl) surfactants, and anionic surfactants may be in acid form or in the form of their sodium or potassium salts.
[0125] Suitable anionic surfactants are those having the structure CH3(CH2) a CH2(CH2CH=CH) b CH2(CH2) c It may contain CH2(C=O)N(CH3)CH2CO2X (wherein a=1 to 8; b=0 to 2; c=0 to 6; and X=H, Na, or K).
[0126] Examples of alkanoyl sarcosinates include those of the formula: R 1’ -CO-N(CH3)-CH2-COO - ; and R 1’ -CO-N(CH3)-CH2-SO3 - (where R1’ is saturated or unsaturated C 5~24 Alkyl, C 7~19 Alkyl, or C 11~17 alkyl), and, for example, their sodium or potassium salts.
[0127] Examples of suitable alkanoyl sarcosinates, and their acid or salt forms, include N-lauroyl sarcosine, sodium lauroyl sarcosinate, sodium palmitoyl sarcosinate, sodium stearoyl sarcosinate, N-methyl-N-(1-oxotetradecyl)-glycine sodium salt, sodium caproyl sarcosinate, sodium capryloyl sarcosinate, N-methyl-N-(1-oxo-9-octadecen-1-yl)-glycine, sodium salt, sodium oleoyl sarcosinate, and sodium linoleoyl sarcosinate.
[0128] Anionic surfactants may be present in buffers or other suitable aqueous compositions according to the present disclosure in the range of about 0.06% to about 0.2% or about 0.08% to about 0.16%.
[0129] The composition can be used in flow cytometry and therefore may contain additional components, including, but not limited to, one or more of any suitable carrier, stabilizer, buffer, salt, chelating agent (e.g., EDTA), or preservative. The composition may also contain one or more additional surfactants in addition to the zwitterionic surfactant and / or anionic surfactant described herein. Non-limiting examples of the one or more additional surfactants include polysorbates, such as TWEEN® 20 (polyoxyethylene sorbitan monolaurate) and TWEEN® 80 (polyoxyethylene sorbitan monooleate). The carrier may be an aqueous solution, such as water, saline, alcohol, or a physiologically compatible buffer, such as Hank's solution, Ringer's solution, or physiological saline buffer. The carrier may also contain formulating agents, such as suspending agents, stabilizing agents, and / or dispersing agents. The composition may also contain a buffer or pH adjuster; typically, the buffer is a salt prepared from an organic acid or base. Representative buffers include salts of organic acids such as citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid; tristromethamine hydrochloride, or phosphate buffers.
[0130] The composition may include a protein stabilizer selected from the group consisting of bovine serum albumin (BSA or "Fraction V"), casein, and gelatin. The protein stabilizer may be BSA, a commercially available bovine serum albumin protein derived from cows. The protein stabilizer may be present in a buffer or other suitable aqueous composition according to the present disclosure at about 0.1-5 mg / mL, about 0.5-3 mg / mL, or about 2 mg / mL.
[0131] The stabilizer may be gelatin, a protein, usually derived from collagen obtained from animal body parts. It is brittle when dry and rubbery when wet. After hydrolysis, it may also be called hydrolyzed collagen, collagen hydrolysate, gelatin hydrolysate, hydrolyzed gelatin, and collagen peptides. Several types of gelatin are commercially available, including gelatin type A, gelatin type B, Prionex® highly purified gelatin type A, and cold-water fish gelatin.
[0132] The composition may also include any suitable preservative. The preservative may be an antioxidant, a biocide, or an antimicrobial. The preservative may be an inorganic salt. The preservative may be sodium azide. The preservative may be present in a concentration range of about 0.01 to about 1%, about 0.05% to about 0.5%, or about 0.1%. polymer dyes
[0133] In another embodiment, the composition may be used with a polymer dye. The polymer dye may be a fluorescent polymer dye or a fluorescent polymer tandem dye. Polymer dyes are particularly useful for analyzing chemical and biological target analytes. Because they contain multiple chromophores, they are highly responsive optical reporters and efficient light absorbers. The polymer dye conjugate may include any of the fluorescent polymer dyes or fluorescent polymer tandem dyes previously disclosed.
[0134] For example, the polymer dye or tandem polymer dye may be any dye disclosed in published PCT application WO2017 / 180998; U.S. Application No. 2021 / 0047476; U.S. Application No. 2020 / 0190253; U.S. Application No. 2020 / 0147615; U.S. Application No. 2021 / 0108083; U.S. Application No. 2018 / 0224460; U.S. Patent No. 11,034,840; U.S. Patent No. 10,228,375; U.S. Patent No. 10,545,137B2; U.S. Patent No. 10,533,092; U.S. Patent No. 7,214,489; U.S. Patent No. 8,354,239; U.S. Patent No. 8,575,303, each of which is incorporated by reference as if fully set forth in its entirety herein. The polymer dye conjugate may have the structure of any of the water-soluble fluorescent polymer dyes disclosed in Published U.S. Application No. 2020 / 0190253A1, which is incorporated by reference in its entirety as if fully set forth herein. The polymer dye conjugate may have the structure of any of the water-soluble fluorescent polymer dyes disclosed in Published U.S. Application No. 2019 / 0144601, which is incorporated by reference in its entirety as if fully set forth herein.
[0135] The polymer dye or polymer dye conjugate may be any commercially available polymer dye or a polymer dye conjugated to a binding partner. The polymer dye or polymer dye conjugate may comprise a polymer dye excitable by a violet laser. The polymer dye or polymer dye conjugate may comprise a polymer dye excitable by a violet laser, for example, at 405 nm. The polymer dye or polymer dye conjugate may comprise a polymer dye excitable by a violet laser (405 nm).
[0136] In some embodiments, the polymer dye or polymer dye conjugate may comprise SuperNova™ dye (Beckman Coulter, Inc.). SuperNova™ polymers are a new generation of polymer dyes useful for flow cytometry applications. The polymer dye or polymer dye conjugate may comprise SuperNova™ v428, SuperNova™ v605, or SuperNova™ v786 (Beckman Coulter, Inc.). SuperNova™ v428 has unique photophysical properties that result in an extremely bright conjugate when conjugated to an antibody or other binding partner. For example, SuperNova™ v428 (SN v428) (Beckman Coulter, Inc.) is a polymer dye that is optimally excited by a violet laser (e.g., 405 nm), has an excitation maximum at 414 nm, an emission peak at 428 nm, and can be detected using a 450 / 50 bandpass filter or equivalent.
[0137] SuperNova™ v428 is one of the brightest dyes excitable by a violet laser and is therefore particularly suitable for assessing dimly expressed markers. SuperNova™ conjugate antibodies can include anti-CD19 antibody-SuperNova™ v428, anti-CD22 antibody-SuperNova v428, anti-CD25 antibody-SuperNova™ v428, and anti-CD38 antibody-SuperNova™ v428 antibody-polymer dye conjugates.
[0138] SuperNova™ v605 and SuperNova™ v786 (Beckman Coulter, Inc.) are tandem polymer dyes derived from the SuperNova™ v428 polymer dye core. Both share the same absorbance characteristics, with a maximum excitation wavelength of 414 nm. Because the emission peaks of SuperNova™ v605 and SuperNova™ v786 are at 605 nm and 786 nm, respectively, they are optimally detected using 610 / 20 and 780 / 60 nm bandpass filters on a flow cytometer. SuperNova™ v605 and SuperNova™ v786 may be conjugated with, for example, anti-CD19, anti-CD22, anti-CD25, and anti-CD38 antibodies.
[0139] The polymer dye or polymer dye conjugate may comprise a polymer dye excitable by an ultraviolet ("UV") laser. The polymer dye or polymer dye conjugate may comprise a polymer dye excitable by a UV laser at a wavelength of 320 nm to 380 nm, 340 nm to 360 nm, 345 nm to 356 nm, or less than or equal to 380 nm but greater than or equal to 320 nm. The polymer dye or polymer dye conjugate may comprise a UV-excitable polymer dye. The UV-excitable polymer dye or polymer dye conjugate may typically emit light at a wavelength of 380 nm to 430 nm, 406 nm to 415 nm, or less than or equal to 430 nm but greater than or equal to 380 nm.
[0140] The polymer dye or polymer dye conjugate may be Brilliant Violet™ dye (BioLegend® / Sirigen Group Ltd.), such as Brilliant Violet 421™ (excitation maximum 405 nm, emission maximum 421 nm, 450 / 50 filter), Brilliant Violet 510™ (excitation maximum 405 nm, emission maximum 510 nm, 510 / 50 filter), Brilliant Violet 570™ (excitation maximum 405 nm, emission maximum 570 nm, 585 / 42 filter), Brilliant Violet 605™ (excitation maximum 405 nm, emission maximum 603 nm, 610 / 20 filter), Brilliant Violet 650™ (excitation maximum 405 nm, emission maximum 645 nm, 660 / 20 filter), Brilliant Violet 660™ (excitation maximum 405 nm, emission maximum 645 nm, 660 / 20 filter), Brilliant Violet 670™ (excitation maximum 405 nm, emission maximum 670 nm, 660 / 20 filter), Brilliant Violet 680™ (excitation maximum 405 nm, emission maximum 680 nm, 660 / 20 filter), Brilliant Violet 690™ (excitation maximum 405 nm, emission maximum 690 nm, 660 / 20 filter), Brilliant Violet 700™ (excitation maximum 405 nm, emission maximum 690 nm, 660 / 20 filter), Brilliant Violet 710™ (excitation maximum 405 nm, emission maximum 690 nm, 660 / 20 filter), Brilliant Violet 720™ (excitation maximum 405 nm, emission maximum 690 nm, 66 711™ (excitation maximum 405 nm, emission maximum 711 nm, 710 / 50 filter), Brilliant Violet 750™ (excitation maximum 405 nm, emission maximum 750 nm, 780 / 60 filter), Brilliant Violet 785™ (excitation maximum 405 nm, emission maximum 785 nm, 780 / 60 filter). The polymer dye or polymer dye conjugate may include Spark Violet™ 538 (BioLegend, Inc.) (excitation maximum 405 nm, emission maximum 538 nm).
[0141] The polymer dye or polymer dye conjugate may include Super Bright dye (Invitrogen, ThermoFisher Scientific). Super Bright dyes can be excited by a violet laser (405 nm). The Super Bright dye may be Super Bright 436 (excitation maximum 414 nm, emission maximum 436 nm, 450 / 50 bandpass filter), Super Bright 600 (emission maximum 600 nm, 610 / 20 bandpass filter), Super Bright 645 (emission maximum 645 nm, 660 / 20 bandpass filter), or Super Bright 702 (emission maximum 702 nm, 710 / 50 bandpass filter).
[0142] The polymeric dye or polymeric dye conjugate may include BD Horizon Brilliant™ Violet polymeric dye (Becton, Dickinson and Co., BD Life Sciences). The polymeric dye may be BD Horizon Brilliant™ BV421 (450 / 40 or 431 / 28 filter), BV480 (525 / 40 filter), BV510 (525 / 40 filter), BV605 (610 / 20 filter), BV650 (660 / 20 filter), BV711 (710 / 50 filter), or BV786 (786 / 60 filter).
[0143] Polymeric dyes may be synthetically prepared by polymerization of monomers, resulting in a highly conjugated fluorescent backbone. Capping may be performed on the polymer by activation using an appropriate functional group, resulting in a polymer that can be conjugated to a binding partner. Alternatively, the polymer may be activated and conjugated by attaching an appropriate functional group to the polymer backbone. The activated polymer can be conjugated to a binding partner. Any suitable binding partner, for example, an antibody, may be used, followed by purification, for example, by standard procedures. The functional group may be selected from the group consisting of amine, carbamate, carboxylic acid, carboxylate, maleimide, activated ester, N-hydroxysuccinimidyl, hydrazine, hydrazide, hydrazone, azide, alkyne, aldehyde, thiol, and their protecting groups for conjugation to a substrate or binding partner.
[0144] The polymer dye conjugate may include a fluorescent polymer having monomer subunits including, but not limited to, dihydrophenanthrene (DHP), fluorene, and combinations thereof. In some embodiments, the polymer dye conjugate has Formula III: [ka] The dye may include a polymer dye having the structure:
[0145] Each A is independently selected from the group consisting of aromatic and heteroaromatic comonomers. Each A may be substituted with a functional group that will be conjugated to a binding partner.
[0146] Each optional M is independently selected from the group consisting of aromatic comonomers, heteroaromatic comonomers, band gap modifying monomers, optionally substituted ethylene, and ethynylene, and is uniformly or randomly distributed along the polymer backbone. [ka] [ka] [ka] wherein each M may be substituted or terminated with a functional group selected from amine, carbamate, carboxylic acid, carboxylate, maleimide, activated ester, N-hydroxysuccinimidyl, hydrazine, hydrazide, hydrazone, azide, alkyne, aldehyde, thiol, amide, sulfonamide, ether, thioether, thiocarbamate, hydroxyl, iodoacetyl, hydrazide, hydrazino, ketone, phosphine, epoxide, urea, thiourea, thioester, imine, disulfide, and protecting groups thereof for conjugation to another substrate, acceptor dye, molecule, or linking agent; Each R 5 is halogen, hydroxyl, C1-C 12 Alkyl, C2-C 12 Alkenes, C2-C 12 Alkynes, C3-C 12 Cycloalkyl, C1-C 12 Haloalkyl, C1-C 12 Alkoxy, C2-C 18 (Hetero)aryl groups, C2-C 18 (Hetero)aryloxy, C2-C 18 (Hetero)arylamino, carboxylic acid, carboxylate ester, (CH2) x’ (OCH2-CH2) y’ OCH3, and (CH2) x’ (OCH2-CH2) y’ OCF3, wherein each x' is independently an integer from 0 to 20 and each y' is independently an integer from 0 to 50; Each R 1 are independently an ammonium alkyl salt, an ammonium alkyloxy salt, an ammonium oligoether salt, a sulfonate alkyl salt, a sulfonate alkoxy salt, a sulfonate oligoether salt, a sulfonamide oligoether, or a moiety: [ka] and; Each R 2 is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, PEG group, ammonium alkyl salt, ammonium alkyloxy salt, ammonium oligoether salt, sulfonate alkyl salt, sulfonate alkoxy salt, sulfonate oligoether salt, sulfonamide oligoether, or a moiety. [ka] and; Each R 3 is independently selected from the group consisting of H, alkyl, alkene, alkyne, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, and a PEG group; each Z is independently selected from the group consisting of C, O, and N; Each Q is a bond, NH, or NR 4 and CH2; Each subscript n is independently an integer from 0 to 20. may be independently selected from the group consisting of:
[0147] The linker is represented by Formula III as L. Each optional linker, L, may be an aryl or heteroaryl group uniformly or randomly distributed along the polymer backbone and may be substituted with one or more pendant chains terminating in a functional group selected from the group consisting of amine, carbamate, carboxylic acid, carboxylate, maleimide, activated ester, N-hydroxysuccinimidyl, hydrazine, hydrazide, hydrazone, azide, alkyne, aldehyde, thiol, and protecting groups thereof for conjugation to a substrate or binding partner.
[0148] The polymer conjugates of the present disclosure may be1 and G 2
[0023] The termini also include those represented by Formula III as follows:
[0024] The termini may be modified or unmodified. The termini may each be independently selected from the group consisting of aryl or heteroaryl substituted with one or more pendant chains terminating in a functional group selected from hydrogen, halogen, alkyne, optionally substituted aryl, optionally substituted heteroaryl, halogen-substituted aryl, silyl, diazonium salt, triflate, acetyloxy, azide, sulfonate, phosphate, boronate-substituted aryl, boronate ester-substituted aryl, boronate ester, boronic acid, optionally substituted dihydrophenanthrene (DHP), optionally substituted fluorene; amine, carbamate, carboxylic acid, carboxylate, maleimide, activated ester, N-hydroxysuccinimidyl, hydrazine, hydrazide, hydrazone, azide, alkyne, aldehyde, thiol, and protecting groups thereof, which may be conjugated to a substrate or binding partner.
[0149] In the structure of Formula III, a, c, and d define the mol% of each unit, which may each be uniformly or randomly repeated, where each a is 10 to 100% mol%, each c is 0 to 90% mol%, and each d is 0 to 25% mol%; each b is independently 0 or 1; and each m is an integer from 1 to about 10,000.
[0150] In some embodiments, the polymer dye conjugate has Formula I: [ka] (In the formula: each A is independently selected from the group consisting of aromatic comonomers and heteroaromatic comonomers; L 1 , L 2 , and L 3 is a linker moiety; W is a water-soluble moiety; each E is an independently selected chromophore, functional moiety, or binding partner; each B is independently selected from the group consisting of aromatic comonomers, heteroaromatic comonomers, band gap modifying monomers, optionally substituted ethylene, and ethynylene; G 1 and G 2 are independently selected from an unmodified polymer end and a modified polymer end; the subscripts n and m are independently integers ranging from 1 to 10,000; the subscript p is an integer ranging from 0 to 10,000; the sum of the subscripts n, m, and p ranges from 2 to 10,000; The subscript q is 1, 2, 3, or 4; The subscript r is 1, 2, 3, or 4; The subscript s is 0, 1, 2, or 3; The subscript t is 1 or 2, The sum of the subscripts r and s ranges from 1 to 4; A and B are randomly or non-randomly distributed in the conjugate polymer. It may have the structure: L 1 may be a sulfonamide, sulfonamide, sultam, disulfinamide, amide, phosphonamide, phosphonamidate, phosphinamide, or secondary amine. 1 may be a sulfonamide, amide, phosphonamide, or secondary amine. The subscript q can be equal to the sum of the subscripts r and s, where the subscript r can be 1 or 2, and if the subscript r is 1, the subscript s is 0 or 1, and if the subscript r is 2, the subscript s is 0. Each L 3 may be a covalent bond.
[0151] The conjugate polymer has Formula II: [ka] (In the formula: L 1a is a linker moiety; R 1 is selected from the group consisting of H and an amine protecting group The structure may be as follows: Various linkers L as described herein 1a and L 2 can be used for the synthesis of polymers according to Formula I and Formula II, for example: L 1a is a covalent bond, C 1~8 alkylene, 2- to 8-membered heteroalkylene (e.g., divalent alkoxy linkers), C 3~8 Cycloalkylene, C 6~10 Arylene, 5- to 12-membered heteroarylene, 5- to 12-membered heterocyclylene, -NHC(O)L a -, -C(O)NHL a -, -C(O)L a - and combinations thereof; L 2 is a covalent bond, C 1~8 alkylene, 2- to 8-membered heteroalkylene (e.g., divalent alkoxy linkers), C 3~8 Cycloalkylene, C 6~10 Arylene, 5- to 12-membered heteroarylene, 5- to 12-membered heterocyclylene, -L b NHC(O)-, -L b C(O)NH-, -L b C(O)-, -C(O)NHL b -, -C(O)L b - and combinations thereof; L a and L b is C 1~8 may be independently selected from the group consisting of alkylene and 2- to 8-membered heteroalkylene; R 1 may be selected from the group consisting of H and an amine protecting group. A polymer according to Formula II is provided, wherein: L 1a is a covalent bond, C 1~8 Alkylene, 2- to 8-membered heteroalkylene, -NHC(O)L a -, -C(O)NHL a - and -C(O)L a - selected from the group consisting of L 2 is a covalent bond, C 1~8 Alkylene; 2- to 8-membered heteroalkylene, -L b NHC(O)-, -L b C(O)NH-, -L b C(O)-, -C(O)NHL b - and -C(O)L b - selected from the group consisting of; L a and L b is C 1~8 independently selected from the group consisting of alkylene and 2- to 8-membered heteroalkylene; R 1 is selected from the group consisting of H and an amine protecting group). W may comprise one or more ethylene glycol monomers, or W may comprise poly(ethylene glycol). L 3 is the first L 1 Part (or first L 1a the first point of attachment to the L moiety; the second point of attachment to the L moiety 1 Part (or second L 1a and a third point of attachment to the A monomer.
[0152] For example, the present disclosure provides compounds of formula VI: [ka] (In the formula, L 1a is as defined above; L 2 is as defined above; W is as defined above; L 3a is a covalent bond, C 1~8 Alkylene, 2- to 8-membered heteroalkylene, -NHC(O)L a -, -C(O)NHL a - and -C(O)L a - selected from the group consisting of; L a is C 1~8 alkylene and 2- to 8-membered heteroalkylene; the wavy line is the point of attachment to the monomer. Conjugate polymers having two or more chromophores attached thereto are provided, as shown in Each A monomer in a polymer having the structure of Formula I, II, or III may be the same monomer. Each A monomer in a polymer having the structure of Formula I, II, or III may be a different monomer. A may be a fluorescent monomer. A may be a 9,10-phenanthrene dione-based monomer (e.g., a dihydrophenanthrene (DHP)-based monomer), a fluorene-based monomer, or a fluorene oxepin-based monomer.
[0153] Monomer A in the polymer having the structure of Formula I, II, or III is a DHP-based monomer, such as: [ka] (In the formula: each X is independently C or Si; Each Y is independently a CR 1 R 2 or SiR 1 R 2 and; Each R 1 are independently an ammonium alkyl salt, an ammonium alkyloxy salt, an ammonium oligoether salt, a sulfonate alkyl salt, a sulfonate alkoxy salt, a sulfonate oligoether salt, a sulfonamide oligoether, or a moiety. [ka] and; Each R 2 is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, PEG group, ammonium alkyl salt, ammonium alkyloxy salt, ammonium oligoether salt, sulfonate alkyl salt, sulfonate alkoxy salt, sulfonate oligoether salt, sulfonamide oligoether, or a moiety. [ka] and; Each R 3 is independently selected from the group consisting of H, alkyl, alkene, alkyne, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, and a PEG group; each Z is independently selected from the group consisting of C, O, and N; Each Q is a bond, NH, or NR 4 and CH2; Each subscript n is independently an integer from 0 to 20. may be.
[0154] R 1 has the structure shown below: [ka] (wherein Q is NH and each R 3 are independently selected from the group consisting of H, alkyl, alkene, alkyne, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, and a PEG group; and each Z is independently selected from the group consisting of C, O, and N. may have
[0155] DHP monomers have the structure: [ka] (In the formula: each subscript f is independently an integer from 0 to 50; each subscript n is independently an integer from 0 to 20; Each R 2 is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, PEG group, ammonium alkyl salt, ammonium alkyloxy salt, ammonium oligoether salt, sulfonate alkyl salt, sulfonate alkoxy salt, sulfonate oligoether salt, sulfonamide oligoether, or a moiety. [ka] and; Each R 5 are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 20 Cycloalkyl, C1-C 20 Haloalkyl, C1-C 20 Alkoxy, C2-C 26 Aryloxy, C2-C 26 Heteroaryloxy, C2-C 26 Arylamino or C2-C 26 is heteroarylamino; Each Z is independently selected from the group consisting of C, O, and N. may have
[0156] DHP monomer has the structure: [ka] (In the formula: each subscript f is independently an integer from 0 to 50; each subscript n is independently an integer from 0 to 20; Each R 2is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, PEG group, ammonium alkyl salt, ammonium alkyloxy salt, ammonium oligoether salt, sulfonate alkyl salt, sulfonate alkoxy salt, sulfonate oligoether salt, sulfonamide oligoether, or a moiety. [ka] and; Each R 5 are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 20 Cycloalkyl, C1-C 20 Haloalkyl, C1-C 20 Alkoxy, C2-C 26 Aryloxy, C2-C 26 Heteroaryloxy, C2-C 26 Arylamino or C2-C 26 is heteroarylamino; Each Z is independently selected from the group consisting of C, O, and N. may have
[0157] Monomer A in the polymer having the structure of Formula I, II, or III is a fluorene-based monomer, such as: [ka] (In the formula, X, Z, R 1 , R 2 , R 5 , subscript n, subscript f are as defined herein) may be.
[0158] R 1 Groups and R 2groups such as ammonium alkyl salts, ammonium alkyloxy salts, ammonium oligoether salts, sulfonate alkyl salts, sulfonate alkoxy salts, sulfonate oligoether salts, sulfonamide oligoethers, or the structure: [ka] can confer solubility in water / buffer. In some embodiments, for example, the polymer is soluble at levels greater than 10 mg / mL, greater than 15 mg / mL, greater than 20 mg / mL, greater than 25 mg / mL, greater than 30 mg / mL, greater than 35 mg / mL, greater than 40 mg / mL, greater than 45 mg / mL, greater than 50 mg / mL, greater than 60 mg / mL, greater than 70 mg / mL, greater than 80 mg / mL, greater than 90 mg / mL, or greater than 100 mg / mL.
[0159] Monomer A may also be a bridging monomer. For example, bridging monomers of the present invention include: [ka] (In the formula, X, Y, R 2 , and R 5 is as defined above) There is.
[0160] Monomer A in the polymer having the structure of Formula I, II, or III can be an oxepin-based monomer (e.g., a fluorene oxepin-based monomer), such as: [ka] (In the formula, X, R 1 , and R 2 is as defined herein) may be. Tandem Polymer Dyes
[0161] The polymer may have an acceptor dye attached to the backbone, thereby providing for monitoring the emission of the acceptor dye attached to the backbone via energy transfer. Acceptor dyes useful in tandem polymer dyes include, for example, FITC, CY3B, Cy55, Alexa 488, Texas red, Cy5, Cy7, Alexa 750, and 800CW. For example, the acceptor dye may be linked to a linker L: [ka] The polymer may be bonded via As described in U.S. Published Application No. 2020 / 0190253, which is incorporated herein by reference in its entirety, the acceptor dye can also be directly attached to monomer A as group E in the structures of Figures I or II above. The SuperNova tandem dyes, SuperNova v605 and SuperNova v786 (Beckman Coulter, Inc.), are tandem polymer dyes derived from the core SuperNova v428. Both SuperNova v605 and SuperNova v786 share the same absorbance characteristics, with a maximum excitation wavelength of 414 nm. With emission peaks at 605 nm and 786 nm, respectively, they are optimally detected using 610 / 20 and 780 / 60 nm bandpass filters on a flow cytometer. Conjugate dyes
[0162] The polymeric dyes may be conjugated to binding partners of different specificities, e.g., target analyte-specific antibodies, to synthesize binding partner-dye conjugates, e.g., CD19-SN v428, CD20-SN v605, etc.
[0163] The polymeric dyes and polymeric dye conjugates may be formulated using an aqueous buffer. Any suitable aqueous buffer, such as an isotonic aqueous buffer, such as PBS buffer, may be used. The aqueous buffer may contain additives. For example, the aqueous buffer may include BSA, sodium azide, a nonionic surfactant, such as PF-68, and a zwitterionic surfactant, such as Empigen BB®, or an anionic surfactant, such as NLS, as described herein. BSA helps stabilize the conjugate, sodium azide prevents any microbial contamination, and surfactants, such as Empigen BB®, significantly reduce or eliminate nonspecific binding to monocytes and granulocytes. BSA may be present in the range of 0-3 mg / mL, 0.5-2.5 mg / mL, or about 2 mg / mL. Sodium azide may be present in the range of 0-0.05%, 0.05-0.03%, or about 0.01% (w / v). Binding partners
[0164] As used herein, "binding partner" refers to any molecule or molecular complex that can specifically bind to a target analyte. A binding partner may be, for example, a protein (e.g., an antibody or antigen-binding antibody fragment), a small organic molecule, a carbohydrate (e.g., a polysaccharide), an oligonucleotide, a polynucleotide, a lipid, an affinity ligand, an aptamer, or the like. In some embodiments, the binding partner is an antibody or a fragment thereof. Specific binding, in the context of the present invention, refers to a binding reaction that determines the presence of a target analyte in the presence of a heterogeneous population. Thus, under certain assay conditions, a designated binding partner preferentially binds to a particular protein or isoform of a particular protein and does not bind in significant amounts to other proteins or other isoforms present in a sample.
[0165] In some cases, the antibody is intravenous immunoglobulin (IVIG) and / or an antibody from IVIG (e.g., enriched, purified, e.g., affinity-purified). IVIG is a blood product containing IgG (immunoglobulin G) pooled from the plasma of many (e.g., sometimes more than 1,000 to 60,000) normal, healthy blood donors (e.g., in some cases, free of any other proteins). IVIG is commercially available. Aspects of IVIG are described, for example, in U.S. Patent Application Publication Nos. 2010 / 0150942; 2004 / 0101909; 2013 / 0177574; 2013 / 0108619; and 2013 / 0011388, which are incorporated herein by reference.
[0166] When the binding partners are antibodies, they may be monoclonal or polyclonal antibodies. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules that specifically bind to, for example, an antigen in a target analyte. Such antibodies include, but are not limited to, polyclonal, monoclonal, monospecific polyclonal antibodies, antibody mimetics, chimeric, single-chain, Fab, Fab', and F(ab')2 fragments, Fv, and Fab expression libraries. In some cases, the antibodies are monoclonal antibodies of defined subclasses (e.g., IgG1, IgG2, IgG3, or IgG4, IgA, IgD, IgE, IgG2a, IgG2b, IgG3, and IgM). When a combination of antibodies is used, the antibodies may be from the same or different subclasses. For example, the antibodies may be IgG1 antibodies. In some embodiments, the monoclonal antibodies are humanized. Antibody fragments may include molecules such as Fab, scFv, F(ab')2, and Fab' molecules. Antibody derivatives include antibodies or fragments thereof with additions or substitutions, such as chimeric antibodies. Antibodies may be from human or animal sources, from hybridomas, via recombinant methods, or any other method known in the art.
[0167] Binding partners other than antibodies or antibody fragments or derivatives specific for the target analyte may also be used in the present systems and methods. For example, the binding partner may be a nucleic acid or nucleic acid analog, such as an oligonucleotide or PNA probe. In one embodiment, aptamers can be used as specific binding partners. Aptamers are single-stranded DNA or RNA (ssDNA or ssRNA) molecules that can bind with high affinity and specificity to preselected targets, including proteins and peptides. Other binding partners that can bind to the target analyte to form receptor-ligand, enzyme-substrate, enzyme-inhibitor, and enzyme-cofactor pairs may also be used. Specific examples of such binding partner pairs include carbohydrates and lectins, biotin and avidin or streptavidin, folate and folate-binding protein, vitamin B12 and intrinsic factor, protein A and immunoglobulins, and protein G and immunoglobulins. Binding partners that form covalent bonds with the target analyte are also included. Conjugates
[0168] The polymer dye conjugate may include any known polymer dye conjugated to a binding partner using techniques known to those skilled in the art. In some embodiments, the polymer dye may be conjugated to a binding partner to form the polymer dye conjugate using the method of directly modifying the core polymer described in U.S. Published Application No. 2020 / 0190253, which is incorporated herein by reference in its entirety.
[0169] In some cases, the polymeric dye may be conjugated to a binding partner to form a polymeric dye conjugate using the methods described in U.S. Published Application No. 2019 / 0144601, which is incorporated herein by reference in its entirety. The method can be illustrated as follows: [ka]
[0170] SuperNova v428 (SN v428 (Beckman Coulter)) is a bright polymer dye that can be activated with amines for tandem dyes or subsequently with maleimide activation for tandem conjugates. The rigidity of the polymer dye structure helps reduce rotational energy, resulting in brighter emission. SuperNova v428 is one of the brightest dyes excitable by a violet laser and is therefore particularly suitable for evaluation of dimly expressed markers. SuperNova conjugate antibodies can include anti-CD19 antibody-SuperNova v428, anti-CD22 antibody-SuperNova v428, anti-CD25 antibody-SuperNova v428, and anti-CD38 antibody-SuperNova v428 antibody-polymer dye conjugates. target analyte
[0171] The present disclosure also relates to a method for detecting a target analyte in a sample, where the target analyte includes a target antigen and may be a substance, e.g., a molecule, whose abundance / concentration is determined by some analytical procedure. The present invention is designed to detect the presence, and in some cases, the quantity, of a specific target analyte. The term "target analyte" refers to a target molecule, including a target antigen, to be detected in a biological sample, such as a peptide, protein, polynucleotide, organic molecule, sugar and other carbohydrate, lipid, and small molecule. An important aspect of the present disclosure is that the target analyte is contained in a liquid sample and is accessible or will become accessible at some time to bind to a target analyte-specific binding partner of the present invention. The target analyte can be found in a biological sample, for example, a blood sample, a cell line development sample, a tissue culture sample, etc.
[0172] The target analyte may be, for example, a nucleic acid (DNA, RNA, mRNA, tRNA, or rRNA), a peptide, a polypeptide, a protein, a lipid, an ion, a monosaccharide, an oligosaccharide, a polysaccharide, a lipoprotein, a glycoprotein, a glycolipid, or a fragment thereof. The target analyte may be a protein, for example, a structural microfilament, microtubule, and intermediate filament protein, an organelle-specific marker, a proteasome, a transmembrane protein, a surface receptor, a nuclear pore protein, a protein / peptide translocase, a protein folding chaperone, a signaling scaffold, an ion channel, etc. The protein may be an activatable protein or a protein differentially expressed or activated in diseased or abnormal cells, including, but not limited to, transcription factors, DNA and / or RNA binding and modifying proteins, nuclear import and transport receptors, regulators of apoptosis or survival, etc.
[0173] The target analyte may be present on or accessible to the cell surface. Illustrative examples of useful analytes include, but are not limited to: 1) specific cell surface macromolecules and antigens (including hormones, protein complexes, and molecules recognized by cellular receptors), and 2) cellular proteins, DNA, or RNA in permeabilized cells containing abnormal DNA or RNA sequences or abnormal amounts of certain messenger RNAs. The detection of these analytes may be particularly useful in situations where they are contained in and / or are identifiers of rare cells, such as those found in the early stages of various cancers.
[0174] In some examples, the target analyte may be CD2, CD3, CD4, CD8, CD10, CD11c, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD27, CD38, CD45, CD45RA, CD56, CD62L, CD64, CD95, CD103, HLA-DR, IFN-γ, TNF-α, or ZAP-70, or other target analyte of interest. Biological samples
[0175] Non-limiting examples of biological samples include blood, serum, plasma, urine, semen, breast milk, sputum, mucus, buccal swabs, vaginal swabs, rectal swabs, aspirates, needle biopsies, sections of tissue obtained e.g., by surgery or autopsy, plasma, serum, cerebrospinal fluid, lymphatic fluid, external secretions of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, tumors, organs, samples of in vitro cell culture components (including, but not limited to, conditioned medium obtained from cells grown in cell culture medium, putative virally infected cells, recombinant cells, and cellular components).
[0176] The sample in the disclosed methods may be, for example, blood. The blood sample may be whole blood. Whole blood can be obtained from a subject using standard clinical procedures. The sample may be a subset of one or more cells of whole blood (e.g., red blood cells, white blood cells, lymphocytes (e.g., T cells, B cells, or NK cells), phagocytes, monocytes, macrophages, granulocytes, basophils, neutrophils, eosinophils, platelets, or any cells having one or more detectable markers). The sample may be from a cell culture. The sample may naturally contain the target analyte or may be prepared, in whole or in part, via synthetic means. subject
[0177] The subject may be a human (e.g., a patient suffering from or suspected of suffering from a disease), a commercially important mammal in the food chain, including, for example, a cow, steer, pig, goat, sheep, bird, fish, or horse. Samples may also be obtained from domestic pets or companion animals, including, for example, a dog, cat, rabbit, bird, or ferret. The subject may also be an experimental animal used as an animal model of disease or for drug screening, such as a monkey, mouse, rat, rabbit, or guinea pig. The subject may also be an exotic animal, such as a zoo animal or wild animal, such as an elephant, antelope, zebra, bison, giraffe, lion, tiger, leopard, orangutan, gorilla, whale, dolphin, shark, or reptile. reaction vessel
[0178] The reaction vessel disclosed herein may be any vessel in which a reaction between a binding partner or its polymer-dye conjugate and a target analyte can occur. For example, the reaction vessel may be a tube, a plate, a well of a microtiter plate, a chamber, or a slide. In a preferred embodiment, the reaction vessel has a lid or cap so that the binding reaction can occur in a closed environment. substrate
[0179] The reaction vessel contains one or more substrates. The substrate may be any suitable surface, including, but not limited to, plastic, nitrocellulose, cellulose acetate, quartz, and glass. Non-limiting examples of plastics include polystyrene, polypropylene, cycloolefin, and polycarbonate. In some embodiments, the substrate is a membrane. The substrate may be the inner surface of the reaction vessel body, such as a plastic tube or a well of a microtiter plate. The substrate may also be beads. In some embodiments, at least one of the substrates (e.g., membranes) that accept the labeled binding partner is attached to the inner surface of the reaction vessel body. In some embodiments, the membrane substrate is a sheet or roll, which facilitates solution deposition and drying. In some embodiments, the membrane may be cut to separate individual dried reaction spots. In some embodiments, the cut membrane is simply dropped into the reaction vessel. In some preferred embodiments, the cut membrane is attached to the surface of the reaction vessel so that the spots do not escape when liquid is pipetted into or out of the reaction vessel. Liquid samples
[0180] The reaction vessel is configured to receive a liquid sample. The liquid sample used in the present invention is typically obtained as or contains a target analyte dispersed in a predominantly aqueous medium.
[0181] The sample may be, for example, a biological sample, such as blood, bone marrow, spleen cells, lymphocytes, bone marrow aspirate (or any cells obtained from bone marrow), urine (lavage), serum, plasma, saliva, cerebrospinal fluid, lymph, urine, amniotic fluid, interstitial fluid, stool, mucus, breast milk, semen, buccal swab, nasopharyngeal swab, vaginal swab, rectal swab, aspirate, needle biopsy, a section of tissue obtained by, for example, surgery or autopsy, or a tissue (e.g., tumor sample, non-cohesive tissue, non-cohesive solid tumor) sample. The sample may be a blood sample. The blood sample may be a whole blood sample. Whole blood can be obtained from a subject using standard clinical procedures. The sample may be one or more cell subsets of whole blood (e.g., red blood cells, white blood cells, lymphocytes (e.g., T cells, B cells, or NK cells), phagocytes, monocytes, macrophages, granulocytes, basophils, neutrophils, eosinophils, platelets, or any cells with one or more detectable markers). The sample may also be from a cell culture, an in vitro cell culture component (including, but not limited to, conditioned medium obtained from cells grown in cell culture medium, putative virally infected cells, recombinant cells, and cellular components).
[0182] A sample may be any source of biological material and may contain proteins, carbohydrates, and / or polynucleotides that can be obtained directly or indirectly from living organisms. Samples may include, for example, cells, tissues, or bodily fluids, as well as viruses, mycoplasma, and deposits left by living organisms, including fossils. A sample may contain a target analyte. The target analyte may be naturally occurring in a biological sample or may be prepared, in whole or in part, via synthetic means. Labeled binding partner
[0183] The dyes can be conjugated to the binding partner by a variety of linkage chemistries between reactive pairs present on the binding partner and the label. Reactive pairs include, but are not limited to, maleimide / thiol, succinimidyl ester (NHS ester) / amine, azide chemistry, carboxy / EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) / amine, amine / sulfo-SMCC (sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate) / thiol, and amine / BMPH (N-[ ~
[0033] Benzyl-3-(2-methyl-2-propionic acid) hydrazide (TFA) / thiol. Methods for conjugation are well known in the art. Commercial kits for conjugation are also readily available, for example, from Innova biosciences (Cambridge, UK), Novus Biologicals (Littleton, Colo.), and Thermo Fisher Scientific (Waltham, Mass.).
[0184] Either dry or liquid polymer-dye conjugates can be used in the present methods and compositions. The dry polymer-dye conjugates can be prepared using any technique known in the art. Such techniques may be as described in US2019 / 0242882, which is incorporated herein by reference.
[0185] The polymer dye conjugates may be used in compositions according to the present disclosure or may be used directly to stain blood and analyze it in a flow cytometer. Assay System
[0186] Assay systems for quantifying binding molecules using binding partners and fluorescent labels are well known, and examples of such systems include flow cytometers, scanning cytometers, imaging cytometers, fluorescence microscopes, and confocal fluorescence microscopes.
[0187] Flow cytometry is used to detect fluorescence. Several devices suitable for this use are available and known to those skilled in the art. Examples include the BCI Navios, Gallios, Aquios, and CytoFLEX™ flow cytometers.
[0188] The assay may be an immunoassay. Examples of immunoassays useful in the present invention include, but are not limited to, fluorescence luminescence assays (FLA). The assay may also be performed on a protein array.
[0189] When the binding partner is an antibody, antibody or multiple antibody sandwich assays can also be used.Sandwich assays refer to the use of a series of recognition events to build layers of different binding partners and report elements that indicate the presence of a specific analyte.Examples of sandwich assays are disclosed in U.S. Patent No. 4,486,530 and the references therein.
[0190] A light source capable of exciting the polymer is applied to the sample, and light emitted from the conjugate-polymer complex is detected. In a typical assay, the fluorescent polymer-dye conjugates for use in the present invention are excitable with light having a wavelength between about 395 nm and about 415 nm. The emitted light is typically between about 415 nm and about 475 nm. Alternatively, the excitation light may have a wavelength between about 340 nm and about 370 nm, and the emitted light is between about 390 nm and about 420 nm. Applicable
[0191] A composition according to the present disclosure may be monochromatic, i.e., comprise a single polymer-dye conjugate, e.g., a single SN polymer-dye conjugate. For example, a biological sample may be stained using an SN conjugate to monitor or identify a particular cell population, depending on the antibody conjugated to the polymer dye.
[0192] In some embodiments, compositions according to the present disclosure may include a single-color polymeric dye conjugate and a conventional non-polymeric dye conjugate. For example, an SN conjugate may be used in a panel for identifying cell subpopulations in a human whole blood sample by flow cytometry, along with a non-polymeric dye conjugate, such as CD4-FITC, CD7-PE, CD25-ECD, or CD56-PC5.5.
[0193] In some embodiments, one or more compositions according to the present disclosure may be contacted with a biological sample, such as a blood sample. For example, the biological sample may be stained with a composition comprising multiple SN conjugates to monitor or identify specific cell populations depending on the antibodies conjugated to the polymeric dyes. In some embodiments, two or more, three or more, or four compositions according to the present disclosure may be contacted with the biological sample. In some embodiments, a composition comprising multiple polymeric dye conjugate compositions may further comprise a non-polymeric dye conjugate, such as CD4-FITC, CD7-PE, CD25-ECD, or CD56-PC5.5, in a panel for identifying cell subpopulations in a human whole blood sample by flow cytometry. [Example]
[0194] The present invention may be better understood by reference to the following examples, which are provided for illustrative purposes only and are not intended to be limiting of the invention to the examples given herein. Example 1 Preparation of DHP polymer composites [ka]
[0195] Method 1: In a round-bottom flask, dibromo DHP monomer and diboronic acid DHP monomer (1:1) described in WO2017 / 180998 were placed in a DMF-water mixture and purged with nitrogen for 10 minutes. Approximately 20 equivalents of CsF and 10% Pd(OAc)2 were mixed under nitrogen and heated to 80°C. Polymerization was monitored using UV-Vis spectroscopy and SEC chromatography. A capping agent containing an appropriate functional group (selected from G1) was then added to the reaction mixture, followed by a second capping agent (selected from G2) after 3 hours. After the reaction, the crude reaction mixture was evaporated and passed through a gel filtration column to remove small organic molecules and low-MW oligomers. The crude polymer was then passed through a tangential flow filtration system equipped with a 100K MWCO membrane. The filtrate was washed with 20% ethanol until the absorbance decreased.
[0196] Method 2: Alternatively, polymerization can be carried out by the self-polymerization of the bromoboronic acid ester of the DHP molecule. In a round-bottom flask, the DHP bromoboronic acid ester was placed in a DMF-water mixture and purged with nitrogen for 10 minutes. Approximately 10 equivalents of CsF and 5% Pd(OAc)2 were mixed under nitrogen and heated to 80°C. Polymerization was monitored using UV-Vis spectroscopy and SEC chromatography. A capping agent containing an appropriate functional group (selected from G1) was then added to the reaction mixture, followed by a second capping agent (selected from G2) after 3 hours. After the reaction, the crude reaction mixture was evaporated and passed through a gel filtration column to remove small organic molecules and low-MW oligomers. The crude polymer was then passed through a tangential flow filtration system equipped with a 100K MWCO membrane. The filtrate was washed with 20% ethanol until the absorbance decreased.
[0197] Method 3: In a round-bottom flask, both dibromodihydrophenanthrene and diboronic acid dihydrophenanthrene monomers (1:1) were dissolved in a THF-water (4:1) mixture containing 10 equivalents of K2CO3 and 3% Pd(PPh3)4. The reaction mixture was placed in a Schlenk line and degassed using three freeze-pump-thaw cycles. It was then heated to 80 °C under nitrogen with vigorous stirring for 18 h. A capping agent (selected from G1) containing an appropriate functional group was then added to the reaction mixture via cannula under excess nitrogen pressure. After 3 h, a second capping agent (selected from G2) was added. After the reaction, the crude reaction mixture was evaporated and passed through a gel filtration column to remove small organic molecules and low-MW oligomers. The crude polymer was then passed through a tangential flow filtration system equipped with a 100K MWCO membrane. The filtrate was washed with 20% ethanol until the absorbance decreased.
[0198] Method 4: Alternatively, polymerization can be carried out by the self-polymerization of the bromoboronic acid ester of the dihydrophenanthrene molecule. Dihydrophenanthrene bromoboronic acid ester was placed in a round-bottom flask and dissolved in a 4:1 THF-water mixture containing 10 equivalents of K2CO3 and 3% Pd(PPh3)4. The reaction mixture was placed in a Schlenk line and degassed using three freeze-pump-thaw cycles. It was then heated to 80 °C under nitrogen with vigorous stirring for 18 h. A capping agent containing an appropriate functional group (selected from G1) was then added to the reaction mixture via cannula under excess nitrogen pressure. After 3 h, a second capping agent (selected from G2) was added. After the reaction, the crude reaction mixture was evaporated and passed through a gel filtration column to remove small organic molecules and low-MW oligomers. The crude polymer was then passed through a tangential flow filtration system equipped with a 100K MWCO membrane. The filtrate was washed with 20% ethanol until the absorption decreased. Example 2 Preparation of fluorene-DHP copolymer conjugates [ka]
[0199] Method 1: In a round-bottom flask, both dibromoDHP and diboronic acid fluorene monomer (1:1) were placed in a DMF-water mixture and purged with nitrogen for 10 minutes. Approximately 20 equivalents of CsF and 10% Pd(OAc)2 were mixed under nitrogen and heated to 80°C. Polymerization was monitored using UV-Vis spectroscopy and SEC chromatography. A capping agent containing an appropriate functional group (selected from G1) was then added to the reaction mixture, followed by a second capping agent (selected from G2) after 3 hours. After the reaction, the crude reaction mixture was evaporated and passed through a gel filtration column to remove small organic molecules and low-MW oligomers. The crude polymer was then passed through a tangential flow filtration system equipped with a 100K MWCO membrane. The filtrate was washed with 20% ethanol until the absorbance decreased.
[0200] Method 2: In a round-bottom flask, both dibromofluorene and diboronic acid DHP monomers (1:1) were placed in a DMF-water mixture and purged with nitrogen for 10 minutes. Approximately 20 equivalents of CsF and 10% Pd(OAc)2 were mixed under nitrogen and heated to 80°C. Polymerization was monitored using UV-Vis spectroscopy and SEC chromatography. A capping agent containing an appropriate functional group (selected from G1) was then added to the reaction mixture, followed by a second capping agent (selected from G2) after 3 hours. After the reaction, the crude reaction mixture was evaporated and passed through a gel filtration column to remove small organic molecules and low-MW oligomers. The crude polymer was then passed through a tangential flow filtration system equipped with a 100K MWCO membrane. The filtrate was washed with 20% ethanol until the absorbance decreased.
[0201] Method 3: Dibromodihydrophenanthrene and diboronic acid fluorene monomers (1:1) were placed in a round-bottom flask and dissolved in a 4:1 THF-water mixture containing 10 equivalents of K2CO3 and 3% Pd(PPh3)4. The reaction mixture was placed in a Schlenk line and degassed using three freeze-pump-thaw cycles. It was then heated to 80 °C under nitrogen with vigorous stirring for 18 h. A capping agent (selected from G1) containing an appropriate functional group was then added to the reaction mixture via cannula under excess nitrogen pressure. After 3 h, a second capping agent (selected from G2) was added. After the reaction, the crude reaction mixture was evaporated and passed through a gel filtration column to remove small organic molecules and low-MW oligomers. The crude polymer was then passed through a tangential flow filtration system equipped with a 100K MWCO membrane. The filtrate was washed with 20% ethanol until the absorbance decreased.
[0202] Method 4: Dibromofluorene and diboronic acid dihydrophenanthrene monomers (1:1) were placed in a round-bottom flask and dissolved in a THF-water (4:1) mixture containing 10 equivalents of K2CO3 and 3% Pd(PPh3)4. The reaction mixture was placed in a Schlenk line and degassed using three freeze-pump-thaw cycles. It was then heated to 80 °C under nitrogen with vigorous stirring for 18 h. A capping agent containing an appropriate functional group (selected from G1) was then added to the reaction mixture via cannula under excess nitrogen pressure. After 3 h, a second capping agent (selected from G2) was added. After the reaction, the crude reaction mixture was evaporated and passed through a gel filtration column to remove small organic molecules and low-MW oligomers. The crude polymer was then passed through a tangential flow filtration system equipped with a 100K MWCO membrane. The filtrate was washed with 20% ethanol until the absorption decreased. Example 3 Comparison of fluorescence emission spectra
[0203] A comparison of the fluorescence emission spectra of fluorene (Fl-Fl), dihydrophenanthrene (DHP-DHP), and fluorene-DHP (DHP-Fl) polymers was performed. After excitation at 405 nm, the DHP-containing polymers exhibited a significant difference in their fluorescence maxima at 426–428 nm, while the fluorene-based polymers exhibited a maximum wavelength of 421 nm, as shown in Figure 1A. Example 4 Comparison of absorption spectra
[0204] The absorption spectra of both fluorene (Fl-Fl) and dihydrophenanthrene (DHP-DHP) polymers were measured. The DHP-DHP polymer (black curve) exhibits lambda max (λmax) at 390 and 410 nm, as shown in Figure 1B, while the Fl-Fl (gray curve) polymer exhibits lambda max (λmax) at approximately 400 nm. The samples were measured at different concentrations. Example 5 Polymer Dye Properties
[0205] The polymeric dyes of the present disclosure have been found to have certain physical and chemical properties, such as absorption, fluorescence, brightness, molecular weight, polydispersity, dye to protein ratio when conjugated to an antibody, etc. Preferred ranges for these parameters are shown in Table 1A.
[0206] [Table 1A]
[0207] The excitation and emission spectra of the tandem polymers were measured: excitation was at the polymer maximum (405 nm), and emission was observed from various acceptor dyes attached to the backbone. Example 6 Experiments with unconjugated dyes
[0208] Blood samples were stained with the unconjugated polymer dye SN v605 (antibody-free) with Empigen BB® and with Empigen BB® and analyzed by flow cytometer. As shown in the bottom right of Figure 2, the presence of Empigen BB® effectively reduced the nonspecific interaction of the fluorescent polymer conjugated to a binding partner with white blood cells in the blood. In Figure 2, blood samples were stained with the fluorescent polymer dye SN v605 without an antibody and analyzed by flow cytometer. In the bottom left of Figure 2, it is clear that the polymer dye without Empigen BB® binds nonspecifically to monocytes / granulocytes. Without wishing to be bound by any particular theory, it is likely that the polymer adsorbs to the cell surface of monocytes and granulocytes. When EMPIGEN BB® is added, the cell surface is blocked by the EMPIGEN BB® molecules, and non-specific binding of the polymer to monocytes and granulocytes is substantially reduced.
[0209] With EMPIGEN BB® added to the polymer, the dot plot appears similar to that of the unstained sample in the top panel of Figure 2, which does not contain any polymer. The diffusion of the granulocyte population corresponds to the unstained tube, suggesting that the nonspecific interaction of the polymer dye with monocytes and granulocytes is dramatically reduced when EMPIGEN BB® is added to the polymer dye. Example 7 Experiments with the conjugated dye SN 605-CD20
[0210] EMPIGEN BB® was formulated with a conjugate described herein (e.g., SN605-CD20, SN786-CD103, and SN428 conjugates), bovine serum albumin (BSA; 2 mg / mL), sodium azide (0.1%), and pluronic F-68 (a polyethylene oxide-polypropylene oxide-polyethylene oxide nonionic triblock copolymer) at a dose of 0.12% per 10 μl of conjugate.
[0211] CD20 is a B-lineage cell marker that is expressed during pre-B lymphocyte development, persists in B lymphocyte development, and is lost upon plasma cell differentiation. CD20 is not expressed on other leukocyte populations, including monocytes, granulocytes, and NK cells. Figure 3 shows the performance of the SN 605-CD20 conjugate without and in the presence of EMPIGEN BB®.
[0212] The percentage of non-specifically bound granulocytes decreased with the use of EMPIGEN BB® (see "P2" gate in the dot plot), and the functional profile of the conjugate was also unchanged, as the percentage of the positive population was similar in both cases (see "P1" gate in the dot plot).
[0213] To confirm the effect of EMPIGEN BB®, two lots of SN 605-CD20 conjugate were tested in the presence and absence of EMPIGEN BB®. Mean fluorescence intensity (MFI) was compared to the autofluorescence of monocytes from unstained samples (median fluorescence intensity of the negative population (MdFI)). The results, shown in Figure 4, demonstrate that in the presence of surfactant, nonspecific interactions on monocytes were reduced to 75% and 67% for SN605 CD20 conjugate lots 1 and 2, respectively. A similar effect (reduced nonspecific binding) was observed on granulocytes, although the percentage reduction was less pronounced (13.7% and 17.7% for lots 1 and 2, respectively; Figure 5). Example 8 Experiments with conjugated dye SN 786-CD103
[0214] Because the CD103 conjugate is not normally expressed in normal whole blood, the test is performed on a cell line (MOLT16). Because there is no CD103 expression in normal blood, there should be no positive signal. However, due to nonspecific interactions, the SN786 CD103 conjugate also tends to bind to whole blood. Adding EMPIGEN BB® to this formulation helps to contain nonspecific interactions. This is shown in Figure 6.
[0215] Two lots of SN 786-CD103 conjugate were tested in the presence and absence of EMPIGEN BB®, and the autofluorescence of the monocyte and granulocyte populations (MdFI of the negative population) was compared to an unstained sample. As shown in Figure 7, the signal from nonspecific binding of the conjugate to monocytes was reduced by 149.3% and 202.1% for Lot 1 and Lot 2 of the SUPERNOVA™ conjugate, respectively. The same effect (reduced nonspecific binding) was observed for the granulocyte population as well, with a reduction of 150.8% and 253% for Lot 1 and Lot 2, respectively, as shown in Figure 8. Example 9 Effect of zwitterionic detergents on monocyte background reduction using SN 428 conjugates
[0216] The efficiency of the zwitterionic detergent EMPIGEN BB® in reducing nonspecific binding to monocytes was evaluated. Other populations, i.e., lymphocytes and granulocytes, were also studied to assess the detergent's impact on MFI and cell percentages.
[0217] The experimental conditions were generally as follows: CD19-SN 428 (Lot D19-094, polymer lot RDS-042919 (82.7 kD), 1 dose (0.5 μg / test). CD22-SN 428 (Lot D19-109, polymer lot WX-20190624 (86.4 kD), 1 dose (0.5 μg / test). CD25-SN 428 (Lot D19-107, polymer lot RDS-062419 (72.8 kD), 1 dose (0.5 μg / test). · Becton Dickinson CD19, CD22 and CD25-BV 421, commercial dose 1x. Three doses of EMPIGEN BB® were prepared as final conjugate formulations: 0.06%, 0.12%, and 0.2%. 10 μL of sample and 100 μL of whole blood were added. Two donors were tested and lysed using VersaLyse (a lysing solution used to lyse red blood cells, Beckman Coulter, Inc.) + Fix, one wash. Navios flow cytometer acquisition at FL9.
[0218] The required number of tubes was prepared, where "number of tubes" depended on the performance being tested. The calculated volume of conjugated antibody (at the required dose) was added to each tube. Whole blood (100 μL) was added to each tube. The tubes were gently vortexed for 15 seconds and incubated for 15 to 20 minutes at room temperature (18-25°C) protected from light. VersaLyse and IOTest3 fixative mixture (2 mL of Versalyse Ref. A09777 + 50 μL of IOTest3 fixative Ref. A07800) was added to the tubes. The tubes were immediately vortexed for 1 second and incubated for 10 minutes at room temperature (18-25°C) protected from light. The tubes were centrifuged at 300 g for 5 minutes at room temperature, the supernatant was removed by aspiration, and the cell pellet was resuspended using 3 mL of PBS 1x. The tubes were centrifuged again at 300 g for 5 min at room temperature (18–25°C), the supernatant was removed by aspiration, and the cell pellet was resuspended using 0.5 ml of PBS 1× or PBS 1× formaldehyde 0.1% (can be obtained by diluting 1 ml of PBS 1× + 12.5 μl of IOTest3 fixative 10×).
[0219] In cytometry, compensation is the mathematical correction of signal overlap between channels of different fluorochrome emission spectra. Therefore, this compensation factor was used to exclude signal spillover into other undesired channels. Manual compensation was performed to evaluate conjugate performance.
[0220] The raw data obtained for two donors using the CD19, CD22, and CD25 SUPERNOVA® v428 conjugate, the data normalized to the no EMPIGEN™ condition, and the final % reduction in monocyte background staining are shown in Table 1B. The data show that in the presence of Empigen BB®, nonspecific background monocyte binding was substantially reduced by between 52 and 73% compared to the no EMPIGEN® condition, where monocyte background was greatest.
[0221] [Table 1B]
[0222] Data showing the effect of Empigen BB® on background reduction of granulocytes are shown in Table 2. Granulocyte background reductions were observed ranging from 4 to 21% compared to the no-EMPIGEN® condition, which had the highest granulocyte background.
[0223] [Table 2]
[0224] Table 3 shows the effect of EMPIGEN® on the positive lymphocyte population: the presence of EMPIGEN® did not induce a significant change in the positive signal for lymphocytes when compared to the condition without EMPIGEN®.
[0225] [Table 3]
[0226] The data in Tables 1-3 are summarized in Figures 11-15.
[0227] Table 4 describes additional experiments and shows the percent reduction relative to background monocytes and granulocytes.
[0228] [Table 4] Example 10 Effect of EMPIGEN BB® on sample cell integrity
[0229] EMPIGEN BB® is a surfactant and therefore may result in permeabilization of cell membranes, causing cell death. From the studies described herein, it was concluded that the concentrations of EMPIGEN BB® used with the polymer-dye conjugates did not induce permeabilization or death of whole blood cells and did not affect the performance of the conjugates.
[0230] Micelle concentration studies were performed in the samples and during staining to ensure that the critical micelle concentration (CMC) was not exceeded. Referring to Table 5, which shows an evaluation of the CMC in the conjugate formulation and during staining. CMC studies were performed in the conjugate formulation and during staining in 100 μL of whole blood. Experiments were performed to evaluate the effect of the addition of EMPIGEN BB® on whole blood cell integrity and on peripheral blood mononuclear cells (PMBCs).
[0231] [Table 5]
[0232] The percentage of dead cells in whole blood samples containing 7-AAD was evaluated. 7-AAD is a DNA marker that stains positive when the cell membrane is permeable. CD19-SNv428 D19-094 without EMPIGEN BB® (negative control) and with 0.06%, 0.12%, and 0.2% EMPIGEN BB® was tested with whole blood from four donors containing 7-ADD to evaluate the percentage of dead cells in each condition. The goal of the experiment was to determine whether the percentage of dead cells increased with EMPIGEN BB® concentration.
[0233] Two whole blood samples stored for more than 24 hours were included as positive controls for 7-AAD staining.
[0234] Protocol for 7-AAD staining: 100 μl whole blood + 10 μl CD19-SNv428+ / - Empigen, incubate for 20 minutes. Lyse using Versalyse, wash once, Resuspend in 500 μl 1x PBS Add 20 μl of 7-AAD (Ref B88526) and incubate for 15-20 minutes. Navios flow cytometer acquisition: FL4 for 7-AAD, FL9 for CD19-SNv428
[0235] The data is shown in FIG.
[0236] Finally, EMPIGEN BB® has proven effective in reducing nonspecific interactions of the polymer dye conjugates described herein (SN 605-CD20, SN786-CD103, SN428-CD25, SN428-CD19, and SN428-CD22). EMPIGEN BB® effectively reduces nonspecific background binding with monocyte and granulocyte populations when tested against the five specificities of the conjugates. This efficiency of EMPIGEN BB® is donor-independent. Clear differences in the reduction of nonspecific monocyte withdrawal were observed when the conjugates were compared with BV786-CD103 and BV 421. In addition to its performance, the presence of EMPIGEN BB® and the polymer dye conjugates did not induce whole blood cell membrane permeabilization or whole blood cell death at concentrations up to at least 0.2% in the composition. Example 11 Effect of nonionic surfactants
[0237] The non-ionic detergents Tween®-20, tergitol, NP-40, and Pluronic F-68 (PF-68) were additional detergents / detergents tested to remove non-specific binding of the conjugates described herein to monocytes. Figure 9 shows the inefficiency of Tween®-20 and PF-68 in avoiding non-specific binding of the conjugates to monocytes. Example 12 The effects of protein blockers
[0238] The problem of nonspecific interactions with monocytes was also observed with conventional tandem dyes (e.g., PC5, PC5.5, PC7, AA700, available from Beckman Coulter, Inc.). To overcome this problem, we considered that the known protein blockers BSA-ox (oxidized BSA) and BSA-Cy5-ox (oxidized Cy5-BSA) could block nonspecific binding. However, we found that BSA, BSA-ox, and BSA-Cy5-ox were all ineffective in controlling the nonspecific interactions of the polymer-dye conjugates with granulocytes / monocytes. See Figure 10. Example 13 Effect of anionic surfactants on nonspecific binding
[0239] The anionic surfactant N-lauryl sarcosine (NLS) was found to be effective at reducing nonspecific staining of monocytes and granulocytes at concentrations of 0.16% and 0.08% (w / v). [ka]
[0240] NLS is an anionic surfactant with a CMC of 14.57 mM (30° C.). Sodium NLS was evaluated to determine the effective concentration for blocking nonspecific binding of a polymer dye conjugate (SN v605-CD20) to monocytes and granulocytes.
[0241] In this example, different concentrations of NLS (0.16%, 0.08%, 0.04%, and 0.02% w / v) were formulated with SN v605CD20 conjugate in the presence of BSA and sodium azide, and peripheral blood samples were stained using flow cytometry.
[0242] Figures 17A-E show dot plots of blood samples in the absence and presence of different concentrations of conjugates with / without Empigen / including NLS. A dot plot of a peripheral blood sample without single-color conjugate is shown in Figure 17A, and the absence of a population in the CD20+ gate is evident.
[0243] A positive control dot plot of a peripheral blood sample in the presence of CD20-SN v605 single-color conjugate in a buffer composition containing BSA, sodium azide, and the zwitterionic surfactant Empigen BB® as additives is shown in Figure 17B. When compared to the negative control dot plot (Figure 17C), the % populations in the gates "Monocyte non-specific binding" (0.64%) and "Granulocyte non-specific binding" (0.68%) were significantly reduced, demonstrating the effectiveness of Empigen BB® in blocking non-specific binding to monocytes and granulocytes, respectively.
[0244] Negative control dot plots of peripheral blood samples in the presence of CD20-SN v605 single-color conjugate in a buffer composition containing only BSA and sodium azide as additives are shown in Figure 17C. Without surfactant, granulocyte nonspecific staining was 1.20% and monocyte nonspecific staining was 1.63%.
[0245] Test point plots of peripheral blood samples in the presence of CD20-SN v605 monochromatic conjugate in a buffer composition containing BSA, sodium azide, and NLS (0.16% w / v) as additives are shown in Figure 17D. Nonspecific staining of granulocytes was substantially reduced to 0.60% and monocyte nonspecific staining was substantially reduced to 0.39% compared to the negative control (Figure 17C).
[0246] Test point plots of peripheral blood samples in the presence of CD20-SN v605 single-color conjugate in a buffer composition containing BSA, sodium azide, and NLS (0.08% w / v) as additives are shown in Figure 17E. Compared to the negative control (Figure 17C), nonspecific staining of granulocytes was reduced to 0.76% and nonspecific staining of monocytes was reduced to 0.93%.
[0247] The dot plots in Figure 17B (Empigen BB®) show that the % populations in the "Monocyte Non-Specific Binding" and "Granulocyte Non-Specific Binding" gates are very similar when compared to Figures 17D and 17E (NLS), indicating that the efficacy of NLS in blocking non-specific binding to cells is comparable to Empigen at 0.16% and 0.08%.
[0248] For CD20-SN v605, the effective concentration of NLS to reduce or eliminate nonspecific staining on monocytes and granulocytes was found to be 0.16% to 0.08% w / v, thus demonstrating that this concentration range of NLS anionic surfactant is effective in reducing nonspecific binding in single-color fluorescent polymer-dye conjugate compositions.
Claims
1. 1. A method for reducing or eliminating non-specific binding of at least one fluorescent polymer-dye conjugate to white blood cells in a biological sample, the method comprising: contacting the at least one fluorescent polymer-dye conjugate with at least one zwitterionic or anionic surfactant prior to contacting the fluorescent polymer-dye conjugate with the biological sample, or contacting the surfactant with the biological sample prior to contacting the fluorescent polymer-dye conjugate with the biological sample, wherein the contacting results in a reduction in non-specific binding of the at least one fluorescent polymer-dye conjugate to the white blood cells in the biological sample, and wherein the fluorescent polymer-dye conjugate comprises a fluorescent polymer dye conjugated to a binding partner. The method includes:
2. The method of claim 1, wherein the biological sample is a blood sample.
3. The method of claim 1 , wherein the white blood cells are selected from the group consisting of monocytes and granulocytes.
4. The zwitterionic or anionic surfactant has the formula: R 1’ [CO-X(CH 2 ) j ] g -[N + (R 2’ )(R 3’ )] k -(CH 2 ) f -[CH(OH)CH 2 ] h -Y - (In the formula, R 1’ is a saturated or unsaturated C 5~24 is alkyl; X is NH or NR 4 ', where R 4’ is C 1~4 alkyl, O, or S; j is an integer from 1 to 10; g is 0 or 1; R 2’ and R 3’ is independently C 1~4 is alkyl; k is 0 or 1; hydroxyl is unsubstituted or substituted with methyl, ethyl, hydroxymethyl, or hydroxyethyl; f is an integer from 0 to 4; h is 0 or 1; Y is COO, SO 3 , OPO (OR 5’ )O, or P(O)(OR 5’ ) O, where R 5’ is H or C 1~4 is alkyl) and when k=0, the surfactant is in its acid form or in the form of a salt thereof.
5. The surfactant has the formula: R 1’ [CO-X(CH 2 ) j ] g -N + (R 2’ )(R 3’ )-(CH 2 ) f -[CH(OH)CH 2 ] h -Y - (In the formula, R 1’ is a saturated or unsaturated C 5~24 is alkyl; X is NH or NR 4’ where R 4’ is C 1~4 alkyl, O, or S; j is an integer from 1 to 10; g is 0 or 1; R 2’ and R 3’ is independently C 1~4 is alkyl; hydroxyl is unsubstituted or substituted with methyl, ethyl, hydroxymethyl, or hydroxyethyl; f is an integer from 1 to 4; h is 0 or 1; Y is COO, SO 3 , OPO (OR 5’ )O, or P(O)(OR 5’ ) O, where R 5’ is H or C 1~4 is an alkyl residue) 5. The method according to claim 1 , wherein the zwitterionic surfactant compound is of the formula:
6. The zwitterionic surfactant has the formula: R 1’ -N + (CH 3 ) 2 -CH 2 COO - ; R 1’ -CO-NH(CH 2 ) 3 -N + (CH 3 ) 2 -CH 2 COO - ; R 1’ -N + (CH 3 ) 2 -CH 2 CH(OH)CH 2 SO 3 - ;or R 1’ -CO-NH-(CH 2 ) 3 -N + (CH 3 ) 2 -CH 2 CH(OH)CH 2 SO 3 - The method of claim 5, wherein the compound is
7. The zwitterionic surfactant may be selected from the group consisting of almond amidopropyl betaine, apricot amidopropyl betaine, avocado amidopropyl betaine, babassu amidopropyl betaine, behenamidopropyl betaine, behenyl betaine, canola amidopropyl betaine, capryl / capramidopropyl betaine, carnitine, cetyl betaine, cocamidoethyl betaine, cocamidopropyl betaine, cocamidopropyl hydroxysultaine, coco betaine, cocohi Hydroxysultaine, Coco / Oleamidopropyl Betaine, Coco Sultaine, Decyl Betaine, Dihydroxyethyl Oleyl Glycinate, Dihydroxyethyl Soy Glycinate, Dihydroxyethyl Stearyl Glycinate, Dihydroxyethyl Tallow Glycinate, Dimethicone Propyl PG-Betaine, Dolucamidopropyl Hydroxysultaine, Hydrogenated Tallow Betaine, Isostearamidopropyl Betaine, Lauramidopropyl Betaine, Lauryl Betaine, Lauryl Glycinate ...
5. The method of claim 1, wherein the hydroxypropyl sultaine is selected from the group consisting of aryl hydroxysultaine, lauryl sultaine, milk amidopropyl betaine, milk amidopropyl betaine, myristamidopropyl betaine, myristyl betaine, oleamidopropyl betaine, oleamidopropyl hydroxysultaine, oleyl betaine, oliamidopropyl betaine, palmamidopropyl betaine, palmitamidopropyl betaine, palmitoyl carnitine, palm kernel amidopropyl betaine, polytetrafluoroethylene acetoxypropyl betaine, ricinoleamidopropyl betaine, sesamidopropyl betaine, soyamidopropyl betaine, stearamidopropyl betaine, stearyl betaine, tallowamidopropyl betaine, tallowamidopropyl hydroxysultaine, tallow betaine, tallow dihydroxyethyl betaine, undecylenamidopropyl betaine, and wheat germ amidopropyl betaine.
8. The surfactant has the formula: R 1’ [CO-X(CH 2 ) j ] g -(CH 2 ) f -[CH(OH)CH 2 ] h -Y - (In the formula, R 1’ is a saturated or unsaturated C 5~24 is alkyl; X is NH or NR 4 ', where R 4’ is C 1~4 alkyl, O, or S; j is an integer from 1 to 10; g is 0 or 1; hydroxyl is unsubstituted or substituted with methyl, ethyl, hydroxymethyl, or hydroxyethyl; f is an integer from 0 to 4; h is 0 or 1; Y is COO, SO 3 , OPO (OR 5’ )O or P(O)(OR 5’ ) O, where R 5’ is H or C 1~4 is alkyl) 5. The method according to claim 1 , wherein the anionic surfactant is in acid form or in the form of a salt thereof.
9. The anionic surfactant is represented by the formula R 1’ -CO-N(CH 3 )-CH 2 -COO - ;or R 1’ -CO-N(CH 3 )-CH 2 -SO 3 - (In the formula, R 1’ is a saturated or unsaturated C 5~24 is alkyl) 9. The method of claim 8, wherein the anionic surfactant is a compound according to the formula:
10. 9. The method of claim 8, wherein the anionic surfactant is selected from the group consisting of N-lauroyl sarcosine or a salt thereof, sodium lauroyl sarcosinate, sodium palmitoyl sarcosinate, sodium stearoyl sarcosinate, N-methyl-N-(1-oxotetradecyl)-glycine sodium salt, sodium caproyl sarcosinate, sodium capryloyl sarcosinate, N-methyl-N-(1-oxo-9-octadecen-1-yl)-glycine, sodium salt, sodium oleoyl sarcosinate, and sodium linoleoyl sarcosinate.
11. The polymer dye conjugate has Formula III: 【Chemistry 31】 (In the formula, Each A is independently selected from the group consisting of aromatic comonomers and heteroaromatic comonomers; each M is independently selected from the group consisting of aromatic comonomers, heteroaromatic comonomers, band gap modifying monomers, ethylene, substituted ethylene, and ethynylene, and is uniformly or randomly distributed along the polymer backbone; each L is a linker moiety, or a linker moiety conjugated to a substrate or binding partner; Each G 1 and G 2 are independently selected from an unmodified polymer end and a modified polymer end that is conjugated to a substrate or binding partner; a, c, and d define the mol % of each unit, each of which may be uniformly or randomly repeated, where each a is from 10 to 100% mol %, each c is from 0 to 90% mol %, and each d is from 0 to 25% mol %; Each b is independently 0 or 1; Each m is an integer from 1 to about 10,000.
5. The method of claim 1 , comprising a binding partner conjugated to a polymeric dye having the structure:
12. The method of claim 11 , wherein A comprises a dihydrophenanthrene (DHP moiety), a fluorene moiety, or a DHP moiety and a fluorene moiety.
13. The at least one polymer dye conjugate has Formula I: 【Chemistry 32】 (In the formula, Each X is independently C or Si; Each Y is independently CR 1 R 2 or SiR 1 R 2 and Each R 1 is independently an ammonium alkyl salt, an ammonium alkyloxy salt, an ammonium oligoether salt, a sulfonate alkyl salt, a sulfonate alkoxy salt, a sulfonate oligoether salt, a sulfonamide oligoether, or a moiety: 【Chemical 33】 and Each R 2 is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, a PEG group, an ammonium alkyl salt, an ammonium alkyloxy salt, an ammonium oligoether salt, a sulfonate alkyl salt, a sulfonate alkoxy salt, a sulfonate oligoether salt, a sulfonamide oligoether, or a moiety. 【Chemical Formula 34】 and Each R 3 is independently selected from the group consisting of H, alkyl, alkene, alkyne, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, and a PEG group; each R 4 is L 2 -E; each E is independently a chromophore, a functional moiety, or a binding partner; Each Z is independently selected from the group consisting of C, O, and N; Each Q is a bond, NH, NR 4 , and C.H. 2 are independently selected from the group consisting of: each subscript n is independently an integer from 0 to 20; each M is a unit capable of modifying the polymer bandgap and is uniformly or randomly distributed along the polymer backbone; L is a linker, or a linker conjugated to a substrate or binding partner; Each L2 is a linker; G 1 and G 2 are each independently selected from the group consisting of hydrogen, halogen, alkyne, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halogen-substituted aryl, silyl, diazonium salt, triflate, acetyloxy, azide, sulfonate, phosphate, boronate-substituted aryl, boronate ester-substituted aryl, boronate ester, boronic acid, dihydrophenanthrene (DHP), substituted DHP, fluorene, substituted fluorene; aryl or heteroaryl substituted with one or more pendant chains terminating in a functional group selected from amine, carbamate, carboxylic acid, carboxylate, maleimide, activated ester, N-hydroxysuccinimidyl, hydrazine, hydrazide, hydrazone, azide, alkyne, aldehyde, thiol, and protecting groups thereof; and each G 1 and G 2 is independently unconjugated or conjugated to a substrate or binding partner; a, c, and d each define the mol % of each unit within the structure, which may be uniformly or randomly repeated, where a is from 10 to 100% mol %, c is from 0 to 90% mol %, and each d is from 0 to 25% mol %; Each b is independently 0 or 1; m is an integer from 1 to about 10,000; Each n is independently an integer from 1 to 20. The method of claim 1 , comprising a binding partner conjugated to a polymer having a structure according to 14. The method of claim 13, wherein each L is independently an aryl or heteroaryl group uniformly or randomly distributed along the polymer backbone and substituted with one or more pendant chains terminating in a functional group selected from the group consisting of amines, carbamates, carboxylic acids, carboxylates, maleimides, activated esters, N-hydroxysuccinimidyl, hydrazines, hydrazides, hydrazones, azides, alkynes, aldehydes, thiols, and protecting groups thereof that are conjugated to binding partners.
15. The method according to any one of claims 1 to 4, wherein the binding partner is a molecule or molecular complex capable of specifically binding to a target analyte.
16. 5. The method of any one of claims 1 to 4, wherein the binding partner is a protein, an affinity ligand, an antibody, or an antibody fragment, and the antibody or antibody fragment is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, an immunoglobulin, an immunologically active portion of an immunoglobulin, a single chain antibody, a Fab fragment, a Fab' fragment, and an F(ab')2 fragment, and an scFv fragment.
17. A fluorescent polymeric dye conjugated to a binding partner; an aqueous buffer; and Zwitterionic or anionic surfactants A composition comprising:
18. 20. The composition of claim 17, further comprising a non-polymeric dye conjugate.
19. the concentration of the zwitterionic or anionic surfactant is below the critical micelle concentration (CMC); and / or 18. The composition of claim 17, wherein the concentration of the surfactant is 0.05 to 0.25% (w / v), 0.06 to 0.20% (w / v), or 0.08 to 0.16% (w / v).
20. 20. The composition of claim 17, wherein the aqueous buffer comprises one or more additional additives selected from the group consisting of a protein stabilizer, a preservative, and an additional surfactant.
21. The composition of any one of claims 17 to 20, further comprising a biological sample, wherein the composition exhibits reduced non-specific binding of the fluorescent polymer dye conjugate to white blood cells in the sample compared to a composition comprising the fluorescent polymer dye conjugate without the zwitterionic or anionic surfactant, and the white blood cells are selected from the group consisting of monocytes and granulocytes.
22. The zwitterionic or anionic surfactant has the formula: R 1’ [CO - X(CH 2 )( j ) g - [N + (R 2’ (R 3’ )) k - (CH 2 )( f - [CH(OH)CH 2 ) h - Y - (wherein, R 1’ is a saturated or unsaturated C 5~24 is alkyl; X is NH or NR 4 ', where R 4’ is C 1~4 alkyl, O, or S; j is an integer from 1 to 10; g is 0 or 1; R 2’ and R 3’ is independently C 1~4 is alkyl; k is 0 or 1; hydroxyl is unsubstituted or substituted with methyl, ethyl, hydroxymethyl, or hydroxyethyl; f is an integer from 0 to 4; h is 0 or 1; Y is COO, SO 3 , OPO (OR 5’ )O, or P(O)(OR 5’ ) O, where R 5’ is H or C 1~4 is alkyl) and when k=0, the surfactant is in its acidic form or in the form of a salt thereof.
23. The fluorescent polymer-dye conjugate has Formula III: 【Chemistry 35】 (In the formula, Each A is independently selected from the group consisting of aromatic comonomers and heteroaromatic comonomers; each M is independently selected from the group consisting of aromatic comonomers, heteroaromatic comonomers, band gap modifying monomers, ethylene, substituted ethylene, and ethynylene, and is uniformly or randomly distributed along the polymer backbone; each L is a linker moiety, or a linker moiety conjugated to a substrate or binding partner; Each G 1 and G 2 is independently selected from an unmodified polymer end and a modified polymer end, and each G 1 and G 2 is independently unconjugated or conjugated to a substrate or binding partner; a, c, and d define the mol % of each unit, each of which may be uniformly or randomly repeated, where each a is from 10 to 100% mol %, each c is from 0 to 90% mol %, and each d is from 0 to 25% mol %; Each b is independently 0 or 1; Each m is an integer from 1 to about 10,000. and / or a binding partner conjugated to a polymeric dye having the structure The fluorescent polymer-dye conjugate has Formula I: 【Chemical Formula 36】 (In the formula, Each X is independently C or Si; Each Y is independently CR 1 R 2 or SiR 1 R 2 and Each R 1 is independently an ammonium alkyl salt, an ammonium alkyloxy salt, an ammonium oligoether salt, a sulfonate alkyl salt, a sulfonate alkoxy salt, a sulfonate oligoether salt, a sulfonamide oligoether, or a moiety: 【Chemical 37】 and Each R 2 is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, a PEG group, an ammonium alkyl salt, an ammonium alkyloxy salt, an ammonium oligoether salt, a sulfonate alkyl salt, a sulfonate alkoxy salt, a sulfonate oligoether salt, a sulfonamide oligoether, or a moiety: 【Chemical Formula 38】 and Each R 3 is independently selected from the group consisting of H, alkyl, alkene, alkyne, cycloalkyl, haloalkyl, alkoxy, (hetero)aryloxy, aryl, (hetero)arylamino, and a PEG group; each R 4 is L 2 -E; each E is independently a chromophore, a functional moiety, or a binding partner; Each Z is independently selected from the group consisting of C, O, and N; Each Q is a bond, NH, NR 4 , and C.H. 2 are independently selected from the group consisting of: each subscript n is independently an integer from 0 to 20; each M is a unit capable of modifying the polymer bandgap and is uniformly or randomly distributed along the polymer backbone; L is a linker or a linker moiety that is conjugated to a substrate or binding partner; Each L2 is a linker; G 1 and G 2 are each independently selected from the group consisting of hydrogen, halogen, alkyne, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halogen-substituted aryl, silyl, diazonium salt, triflate, acetyloxy, azide, sulfonate, phosphate, boronate-substituted aryl, boronate ester-substituted aryl, boronate ester, boronic acid, dihydrophenanthrene (DHP), substituted DHP, fluorene, substituted fluorene; aryl or heteroaryl substituted with one or more pendant chains terminating in a functional group selected from amine, carbamate, carboxylic acid, carboxylate, maleimide, activated ester, N-hydroxysuccinimidyl, hydrazine, hydrazide, hydrazone, azide, alkyne, aldehyde, thiol, and protecting groups thereof; and each G 1 and G 2 is independently unconjugated or conjugated to a substrate or binding partner; a, c, and d each define the mol % of each unit within the structure, which may be uniformly or randomly repeated, where a is from 10 to 100% mol %, c is from 0 to 90% mol %, and each d is from 0 to 25% mol %; Each b is independently 0 or 1; m is an integer from 1 to about 10,000; Each n is independently an integer from 1 to 20.
21. The composition of claim 17, comprising a binding partner conjugated to a polymeric dye having a structure according to
